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RÉSUMÉ
Les gènes HERGJ et KCNQJ codent pour l’expression de sous-unités alpha canalaires
perméables aux ions K. Ces protéines canal participent activement au processus de
repolarisation des myocytes cardiaques conmie dans le phénomène de «réserve de
repolarisation» et ainsi constituent des acteurs déterminants dans l’apparition des
arythmies. L’expression de ces gènes présente une disparité régionale dépendant à la fois de
facteurs de différenciation mais aussi du profil physiopathologique du muscle cardiaque.
Dans cette étude, nous avons identifié l’ensemble des régions promotrices et les sites
d’initiation de la transcription de tous les isoformes de HERGJ et KCNQ]. Nous avons
aussi caractérisé un transactivateur commun, la protéine SPi qui permet de contrôler leur
transcription. Pour la première fois nous apportons des évidences expérimentales montrant
que les gènes codant pour l’expression des canaux ioniques constituent des cibles de
régulation pour les microARNs (miARNs): miR-133 réprimait l’expression de HERGJ et
KCNQ] et miR-1 réprimait l’expression de KCNEJ. Les ARNm codant pour l’expression
de l’ensemble des isoformes HERG1 et KCNQ1 étaient distribuées de façon asymétrique au
sein du muscle cardiaque avec une prédominance dans les cavités de la partie droite du
coeur en comparaison avec la partie gauche. Nous avons observé une hétérogénéité spatiale
de la distribution de KCNQJ et KCNEJ suivant trois axes (interventriculaire, transmural et
apical-basal) avec une disparité notable entre les niveau d’expression des ARNm et des
protéines correspondantes. Cette disparité était associée à une hétérogénéité dans la
distribution spatiale de SPi et miR-1/miR-133. Nos données ont ensuite permis de montrer
clairement que des interactions entre SPi et miR-i/miR-i33 déterminent l’expression des
gènes HERGJ et KCNQJ , par la même, seul le profil d’expression régional de SP-i et miR
1/miR-133 pouvait expliquer la différence régionale reconnue des courants ‘Kr et ‘Ks,
démasquant une implication potentielle dans la genèse des arythmies. Ainsi notre étude a
permis de caractériser un nouvel aspect de la fonction cellulaire des miARNs visant à
réguler l’électrophysiologie cardiaque. Offrant une explication des différences observées
entre les quantités d’ARNm et les niveaux d’expression des protéines issus d’un même
gène.
Mots-clés: HERG1, KCNQ1, Canaux potassiques, Spi, microARNs, miR-i, miR-133,
Arythmies, Différences régionales, Repolarisation.
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ABSTRACT
HERGJ and KCNQJ genes encode two major repolarizïng K channel a
subunits that critically determine the repolarization rate and repolarization reserve in
cardiac celis thereby the likelihood of anhythmias. Expressions of these genes are
regionally heterogeneous and change dynamically depending on differentiation status
and pathologicai states of the heart. Here we identified the core promoter regions and
transcription start sites for ail HERG1 and KCNQJ isoforms, and revealed Spi as a
common transactivator for their transcriptions. We also demonstrated ffiat the mRNA
levels of ail HERG1 and KCNQ] isoforms are asymmetrically distributed within the
heart, being predominant in the right relative to the lefi chamber. Notably, we for the
first time experimentally validated ion charmel genes as targets for microRNA
regulation by showing the ability of miR-133 to repress HERGJ and KCNQJ and of
miR-1 to repress KCNE1. We further demonstrated the spatial heterogeneity of
KCNQJ and KCNEJ distributions along three axes (interventricular, transmural and
apical-basal) and disparity between mRNA and protein expression of ifiese genes, and
the spatial heterogeneity of Spi and miR-1/miR-133 distributions as well. Our data
strongly indicate that the interplay between Spi and miR4/miR-133 determines the
expression levels of HERGJ and KCNQJ genes and the unique regional expression
profiles of Spi and miR-1/miR-133 may be one of the mechanisms for the weli
recognized regional differences of I and I1c, which might have a potential
implication in arrhythmogenesis. Moreover, our study unraveled a novel aspect of the
cellular function of miRNAs in regulating cardiac electrophysiology and offered an
explanation for disparities between mRNA and protein expressions of genes.
Keywords : HERG1, KCNQ1, Potassium channels, Spi, microRNA, miR-1, miR-
133, Arrhythmia, Regional difference, Repolarization.
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1PART I. INTRODUCTION AND REVIEW 0F THE.
LITERATURE
1. Delayed rectifier potassium currents I and I in the heart
1.1 Overview of cardiac action potentïal
The normal electrophysiological behavior of the heart is determined by the
orderly propagation of electrical impulses resulting in rapid depolarization and slow
repolarizafion, thereby generating action potentials in individual myocytes1. The
cardiac action potential (AP) reflects a balance between inward (depolarizing) and
outward (repolarizing) currents. It consists of five phases. Phase O represents
depolarization of the myocytes, in which voltage-gated sodium channels (‘Na) are
rapidly activated to depolarize the celi membrane. Phase 1 of the cardiac AP occurs
right after the peak of depolarization, which underlies an early rapid phase of the
repolarization in ventricular and atrial celis. This rapid repolarization is due to the
inactivation of ‘Na and activation of transient outward potassium current (Ito).
following phase 1 is the long lasting plateau phase 2 repolarization, reflecting the
balance between slowly decreasing inward depolarizing calcium (iCa,L) currents
through L-type calcium channels and gradually increasing outward repolarizing
potassium currents mainly through rapid delayed rectifier potassium curren (Ic). The
net amount of ions fluxing across the ceil membrane during the plateau phase is small,
resulting in high impedance. Therefore a relatively small change in the ion current
can have a significant impact on the membrane potential thereby action potential
duration (APD). Phase 3 repolarization is primarily due to activation of IKr and slow
delayed rectifier potassium channels (Ic), along with inactivation of ‘Ca,L. Phase 4 is
the final stage of the cardiac action potential, during which the ceil membrane retum
to its resting potential, which is accomplished by the outward potassium current (IKI)
through inward rectifier channels. Figure I shows the relationships among different
cardiac ion channels and an AP.
730 ;nV
-$0 rnV
The configuration and duration of AP differ in specific regions (e.g., atrium
versus ventricle; apex versus basal, etc.) as well as in different layers within those
regions (e.g., epicardium, midmyocardium and endocardium) (as shown in Figure
2). These physiologic heterogeneities of cardiac AP are likely due to differential
expression of ion channels. For example, smaller I accounts partly for longer APD
in midmyocardium. Other factors, such as genetic defects (mutations in ion channel
genes), sympathetic regulation, modulation by dmgs and alterations in response to a
variety of diseases (e.g., ischemia, myocardial infarction, hypertrophy, diabetes, etc.),
can exaggerate these heterogeneities generating a substrate for arrhythmogenesis.
HCa
2
0
jIN
t
‘
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3
‘Ki
4
Figure 1. Cardiac action potential and ion channels. Typical ventricular action
potential (AP) with inward currents (downward arrow) and outward currents (upward
arrow). Numbers indicate various phases of an AP (Modified from Schram G, et al.2)
3Atrium
1.2 Biophysical properties of rapid and slow delayed rectifier potassium
channels
1.2.1 Overview 0f ‘K. and I
In cardiac myocytes, voltage-gated potassium (Kv) channels are the primary
determinants of action potential repolarization. In general, based on differences in
time- and voltage-dependent properties and pharmacological sensitivities, there are
two types of cardiac Kv have been distinguished6, transient outward potassium
currents (Ito) and delayed rectifier potassium cunents (IK). Tto rapidly activates and
inactivates when ce!! membrane depolarizes to positive potentia! around -30 mV,
which underlies the early phase (phase 1) of the action potential in atrial and
V.ntricI.
Figure 2. Action potential waveforms are variable in different regions of the
heart. Schematic representation of the heart; AP waveforms recorded in different
regions of the heart are illustrated.
4ventricular cells7. ‘K activate more slowly compared to ‘to following initial
depolarization. Three distinct components, ‘Kur, I and I, comprise the delayed
rectifier potassium current in the heart8”. ‘Kur activates extremely fast (named
ultrarapid), almost instantaneously when compared to the other two components of ‘K•
I activates fast and exhibits a strong inward rectification, and Iic activates very
slowly. While I and I are found in both of atial and ventricle myocytes in different
species (except aduit rodent), ‘Kur exists only in atrial myocytes in most species
(including human)’ 1-16, but flot in human ventricular myocytes and Purkinje fibers,
suggesting that it is a suitable target for specific treatment of atrial arrhythmias. Since
my study is focusing on the regulation of pore forming Œ-subumts of and ‘Ks
channels, for the rest of this chapter, I will mainly discuss these two major
components.
1.2.2 Electrophysiological and pharmacological properties of IKr and I7(s
1.2.2.1 ‘Kr and I in general
I and Ii are distinguished by their kinetics of activation, deactivation and
inactivation, and by their highly variable sensitivity to dmg blockers. They were first
distinguishably recorded in guinea pig atrial and ventricular myocytes, basing on the
distinct differences in time- and voltage-dependent properties’7’9. They have also
been found co-expressed in human atrial and ventricular myocytes’5 6;2021; as well as
in canine42225 and rabbit26’27 ventricles and in canine Purldnje fibers25. In some
species, for example, feline283’ and fetal mice32 and rat33, composes the major
repolarizing current, but it is rapidly supplanted postnatally by a very large It. In
contrast, the currents of IlCj and I are undetectable in small aduit rodent ventricles35,
1.2.2.2 Electrophysiological and pharmacological properties of Iic
I channels activate during the upstroke (Phase 1) and plateau (Phase 2)
phases of an AP. Activation of Ifc starts with precipitous voltage dependence and its
haif-maximal activation appears approximately at the potential of -25 mV. The
amplitude of Ig increases as the membrane potential arises to O mV, and then
decreases upon further depolarization, resulting in a unique ‘bell’ shape of the
current-voltage relationship. Iy activates rapidly and inactivates faster at more
positive potential, and thus limits the time that the channels stay in the open state,
showing strong inward rectification36. On repolarization the rate of recovery from
inactivation through the open state is much more rapid then deactivation, which
resuits in a large outward current in the voltage negative to O mV and provides a basis
for promoting phase 3 repolarization.
I/HERG was originally classified to be a component of ‘K due to its specific
sensitivity to methanesulfonanilide class III antiarrhythmic agent E-403 i37, dofetilide
and d-sotalol38. Ijj./IIERG is also blocked by class E antiarrhythmic agents such as
propafenone39, quinidine40, flecainide4’ and mexiletine42, as well as some other non
cardiovascular drugs (e.g. cisapride43, terfenadine”, astemizole45). Blockage of
Ijf[TERG channels by pharmacological agents is pro-arrhythmic, which will
potentially produce marked QT prolongation and distinctive ventricular tachycardia,
torsades de pointes, or acquired long QT syndrome (LQTS).
1.2.2.3 Electrophysiological and pharmacological properties ofIj
Compared to Ic activates much more slowly when cell membrane
depolarizes to above -30 mV. Its haif-maximal activation is around +20 mV’537468.
I activates much slowly, and an extreme]y long depolarization period is required for
it to reach the steady-state level. I mainly serves as a “repolarization reserve” in
cardiac repolarization in both human atria and ventricles4950, preventing excessive
APD prolongation and development of arrhythmogenic early afierdepolarizations49,
6particularly when Iic is substantial depressed by drugs or in the presence of cardiac
disease.
I is resistant to blockade by methanesulfonanilide antiarrhythmic agents37,
but selectively blocked by chromanols (293B, HMR-1556)51’52. Iic specific blockers
have been developed but flot commercialized because ofthe potential.risk of torsades
de pointes. It has been shown that there is a tendency of developing a homogeneous
APD prolongation in ventricular tissue by blocking iy3.
1.2.3 Contributions ofI and I to repolarization
The relative contributions of Ig and Ijc to repolarization have been broadly
studied in different species for the last two decades. In guinea pig ventricular
myocytes, similar amplitudes of these two currents were recorded when the
membrane potential was set to the potential corresponding to plateau phase of
repolarization, indicating their equal contributions to the repolarization37. Blockade of
either I or I caused a similar moderate prolongation of repolarization, whereas
concomitant blockade of both Ic- and I lcd to a much greater prolongation54. In
rabbit and dog ventricular myocytes, the relatively amplitude of Iic under the similar
condition (membrane potential depolarized to 3O or 4O mV) is larger than Ic2555,
which implicates that the overall contribution of Ic3 to ventricular repolarization is
greater than that of ‘Ks• Therefore, in dog and rabbit (perhaps in human), I may be
more important than I in determining ventricular repolarization. However,
interestingly, when repolarization is delayed pharmacologically or pathologicaÏly, the
prolonged APD will favor activation ofI to restrict the excessive APD prolongation,
reducing the risk of early afierdepolarization (EAD).
72. Molecular composition of 1c and I
2.1 Overview of molecular composition of Ic and I
The molecular identity of Igj and Ic remained unknown until revealed by
molecular genetic analysis of an inherited disease, long QT syndromes. HERG
encodes subunits to form channel complex constituting lic1. KCNQ1 and KCNEÏ
encode subunits that co-assemble to form channels that mediate Mutations in any
of these genes can cause LQTS, a disorder of cardiac repolarization that predisposes
to lethal ventricular arrhythmias.
2.2 Molecular composition of Ii
HERG (Human ether-a-go-go) is a member of the ether-a-go-go (EAG)
channel family originally cloned from a hippocampal cDNA library and was found to
be highly expressed in human heart tissue56. Several independent heterologous
expression studies confirmed that HERG encodes ffie u-subunit underlying 11Cr5758.
HERG has the same channel structure as the other voltage-gated ion channels’960.
Four repeats of six transmembrane domains (Si -S6) constitute each HERG channel
with a reentrant ‘pore-loop’ between $5-$6 to form the channel pore605963. The
biophysical properties of expressed HERG are nearly identical to those of native Iic
in cardiac myocytes5737. Some studies also proposed that additional channels subunits,
minK (KCNE1) or Mink-related peptide 1 (MiRP1 or KCNE2) may associate with
the pore-forming a subunit (HERG) to form the native I6466. Although this notion is
further potentiated by the finding of mutations in KCNE2 gene are associated with
congenital and acquired LQTS6567, but it stiil remains somewhat uncertain and are
challenged by other studies. For examples, Weerapura et al. reported that the
biophysical and pharmacological properties of HERG channel without the co
expression of MiRP1 were quite similar with Ic1 recorded in guinea pig68. And
meanwhile, some other studies have also failed to confirrn the biophysical
interactions between HERG and MiRP169. Mutations in pore-forming a-subunit
8(HERG) or in putative regulatory subunit Mink-related peptide 1 (MiRP-1) of I
chaimels are associated with congenital (LQT2 and LQT6) and acquired long QT
syndrome, which can-ies increased risk of life-threatening cardiac arrhythmias57’65’70’.
Taken together, I is composed primarily of the pore-forming a-subumt
HERG which might be associated with a function-altering 13-subunit MiRP1 or minK,
but the t3-subunits underlying Ifcj, and thefr interactions with HERG are stili under
controversy, and remain to be further investigated.
2.3 Molecular composition ofI
The pore-forming a-subunit KCNQ1 (formerly called KvLQTI) together with
-subunit mink (KCNE1) forms the slow delayed rectifier potassium channel (Ig)
when co-expressed in heterogeneous systems, whule expressing any ofthem alone can
not produce I1c-like current47’7174. KCNQ1 was originally identified with the purpose
of searching for a gene associated wiffi LQTS by the positional cloning
approach72and is found to express strongly in the pancreas and the heart72. KCNQ1
has 676 amino acids which consists of six transmembrane domains and forms typical
pore ioop structure71 75,76 MinK is a single transmembrane protein containing 129
amino acids, and functions as the regulatory accessoiy to increase the macroscopic
current amplitude by siowing the charinel activation kinetics and shifiing the
activation at more positive potential6673’77. Loss-of-function mutations in either
KCNQ1 or minK cause fonns of LQTS (LQTS1 and LQTS5,
respectively)47627’ ;72;78;79
2.4 Isoforms ofHERG1 and KCNQ1
2.4.1 Isoforms ofHERGJ
In mammalian heart, N-terminal spiice variants of ERG have been found in
both human and mouse80’81. The long isoform la (HERG1a) fias 396 amino acids in
the N-terminus, whereas the short isoform lb (HERG15) has only 36 amino acids in
9the N-tenninus8081. The lacking part of isoform lb is important for ifie slow
deactivation process of isoform 1a8084. A recent study proposed that cardiac I
channels are minimally composed of HERG1a and HERG1b Œ-subunits that co
assemble in the membrane83. Jnterestingly, HERG1b subunits co-expressed in
heterologous systems preferentially form heteromultimers with HERG1 a and modify
the deactivation gating properties previousiy attributed to the HERG1a N-terminus84.
A smdy carried out by Nerbonne et al using specific antibodies against the N- and C
tennini of HERG in human, rat and mouse, showed that HERG1 a is expressed in
aduit hearts of ail three species, but there is no detectable expression of HERG1b85.
However, HERG1b was shown to contribute to Ig channel function in the neonatal
hearts86. These findings indicate that there is a developmental change in ERG isoform
expression.
2.4.2 Isoforms ofKCNQ1
Isoform 1 (long isoform) and isoform 2 (short isoform) are the two major
splice variants in the heart when detected at the mRNA level8789. Two isoforms are
different in their N-termini, with deletion of nearly the whole N terminus of isoform
28790. When expressed in a heterologous context, the isoform 2 protein functions as a
dominant negative isoform87. Notably, a detectable amount of protein originating
from isoform 2 transcript has neyer been reported in cardiac tissue91. For convenience,
here we designate the two major isoforms KCNQIa (long isoform or isoform 1) and
KCNQ1b (short isoform or isoform 2).
3. Regional heterogeneities of Ic. and I
There exist marked differences in the densities of Ic1 and Ic in different
myocardial ceil types, which contribute to the regional properties of AP waveforms in
the heart. These intrinsic regional heterogeneities of Ig and ‘Ks help to maintain the
normal heterogeneous property of cardiac AP through out the heart, and thereby
assure the proper propagation of electrical signal. The regional differences are
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reflected in sinoatrial node (SAN), atrioventricular node (AVN), apex versus base,
lefi atrium (LA) versus right atrium (RA), lefi ventricle (LV) versus right
ventricle(RV)) or layers (epicardial (Epi), midmyocardial (Mid) and endocardial
(Endo) ) ofthe atria and ventricles.
3.1 Transmural differences of I- and I
Two independent studies have shown that the density of Ic- in ceils isolated
from guinea pig lefi ventricular free walls was higher in epicardial than in
midmyocardial or in endocardial myocytes, whereas both Ic and Ig densities at the
base of the heart were smaller in sub-endocardial myocytes than those in mid
myocardial and sub-epicardiaÏ myocytes9293. In dog ventricles, I density was found
significantly higher in epicardial and endocardial celis than in midmyocardial (M)
ceils, whereas, Ici density was comparable among ffiose tbree layers22. The lower
density of Ii in the M celis is supposed to contribute to the longer APD in
midmyocardial region22. In rabbit ventricular celis, I density was shown to be
significantly greater in epicardial myocytes than in endocardial myocytes, whereas
the densities of Iic in these two layers were found to be similar94.
3.2 Apex-base dïfferences of ‘Kr and I
A substantial electrophysiological difference between I and Ic was also
recognized along the apico-basal axis of ventricle in some animal species, for
example, in rabbit ventricular myocytes, I density was higher in base than in apex,
whereas the density ofI was fourid to be lower in the base that in the apex55.
3.3 Inter-chamber differences ofIc and Ii
I is larger in lefi atrial free-wall than in right atrium, which accounts for the
shorter APDs in this region in guinea pig95. Two recent studies have investigated the
interventricular differences of Ig and I expression in canine hearts: the density of
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I was found to be comparable between lefi and right ventricles, whereas I density
was almost two-fold higher in right ventricle than in lefi ventricle2396.
3.4 Molecular bases underlying the regional heterogeneities ofI and I
(Discrepancy between mRNA and protein)
The molecular bases for the regional differences in I and Ii have been
evaluated based on differential expressions of the channel subunits at both mRNA
and protein levels. For example, ERG protein levels in dogs are greater in the LA
than in the RA, consistent with a larger Ii. in LA95. Human minK mRNA levels are
flot significantly different among epicardial, midmyocardial, and endocardial tissues88.
However, KCNQ1b (isoform 2, dominant negative spiice variant of KCNQ1)
expresses more abundantly in the midmyocardium, potentially accounting for lower
Ic in M cells88. k ferret, a larger I with more abundant KCNQJ transcripts are
observed in RA than in LA, and ERG mRNA and protein expressions are more
abundant in the apex than in the base, winch is in accordance with I in these
regions2829.
Notably, in addition to the regional difference of I and I subunits’
expressions, there is also a consistent discrepancy between the protein and mRNA
expressions ofthese genes. A typical example is the-well recognized heterogeneity of
Ii. According to the previous studies, KCNQ1 and KCNE1 distribute with
significant inteiventricular gradients (RV>LV) at both mRNA and protin levels,
winch is in agreement with I interventricular difference97. The protein levels of both
KCNQ1 and KCNE1 are higher in apical than in basal area, despite that their mRNA
levels are flot significantly different98. KCNQ1 protein level is greater in Epi than in
Mid99, whereas that of KCNEI is the opposite, and there is flot fransmural difference
in mRNA levels ofKCNQ1 and KCNEI88.
Tremendous work has been done in the past decade regarding the ionic basis
of electrical heterogeneity in different regions of the heart. However, the molecular
bases responsible for these regional heterogeneities are stiil poorly understood: how
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ion channel genes tum on or off and what are the determining factors that control
their differential expressions in the heart.
3.5 Implications of regïonal heterogeneities of 1c. and I in arrhythmogenesis
Under normal physiological conditions, the regional difference is genetically
programmed with a certain pattem with APD gradient from long to short following
the sequence of activation of myocardial mass during an excitation, which constitutes
an intrinsic protection mechanism against arrhythmias which could be induced due to
radial and retrograde excitation propagation. Under pathological situations, the spatial
heterogeneity is abnormally increased and the intrinsic paffem of spatial
heterogeneity may also be broken. These changes render the heart a loss of the
intrinsic antiarrhythmic mechanism and a vulnerability to arrhythmogenesis. For
example, enlarged interventricular differences have been shown to cause acquired
LQTS’°°’101. The spatial heterogeneity of cardiac repolarization is largely due to
diversity and varying densities of repolarizing K currents. IICj and 1ic are the two
most important repolarizing currents responsible for ventricular repolarization. It is
therefore likely that regional heterogeneities of Ii and Ii play important roles in
determining the spatial dispersion ofelectncal activities22.
4. Alterations of delayed rectifier potassium channel (Age and diseases)
4.1 Age-dependent changes in I and I
Expression of both HERG and KCNQJ genes is dynamic depending on
differentiation status and ceil cycle of the ceils, contributing importantly to the
developmental evolution of myocardial AP morphology. For example, I is the sole
component of delayed rectifier K current in fetal day 18 mouse ventricles, yet both
I and ‘Ks can be observed on postnatal day 1. By day 3, Tics is the dominant
component. With flirther development into adulthood, neither 1 nor IK can be
observed32°2. In canine heart, it was found that I is absent or minimal before age 4
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weeks, at which time I is the major repolarizing current95. With progression toward
adulthood, I appears and increases in density while 1 density diminishes. It
appears that expressions ofHERG and KCNQJ genes are tightly controlled by certain
factors according to a defined genetic program related to morphogenesis during
development. Therefore, understanding expression regulation of these genes will
provide a Setter insight on this issue.
4.2 I- and I under pathological conditions
The current densities of I and I in cardiomyocytes are modulated under a
variety ofpathological conditions in different species.
4.2.1 Congenïtal and acquired long QT syndromes
The long QT syndrome is a heart disease in which there is an abnormally long
delay between the depolarization and repolarization of the ventricles of the heart. It is
associated with syncope and sudden cardiac death due to ventricular anhythmias°3. It
could 5e either congenital or acquired, depending on whether it is induced by
mutations in genes or by medications103°4. Two clinical phenotypes of congenital
LQTS have been recognized: The Romano-Ward syndrome (autosomal
dominant)lO5lO6 and the Jerveil-Lange-Nielsen syndrome (autosomal recessive)107.
Romano-Ward syndrome is most common forms of congenital LQTS and is
associated with mutations in Icj, I, and ‘Na channels genes5772108. On the other hand,
Jerveli-Lange-Nielsen syndrome is relatively rare and is normally associated with
deaffiess solely due to defects in The LQTS-associated mutations in the K
channels decrease outward current through Ij or Ic by loss-of-function or dominant
negative mechanisms57’72’°8. Acquired LQTS or drug-induced LQTS is more
common than its congenital counterpart, mainly due to the sensitivity of I (HERG)
to agents with class III antiarrhythmic action109, antifimgal or antihistamine
agenes°’1 and macrolide antibiotics1 12;113 Recent studies have demonstrated that a
number of non-genetic and genetic risk factors67’79”4 could increase susceptibility to
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acquired form of LQTS. Non-genetic factors include female gender, hypokalçmia,
and otherheart diseases”5”6.
To date, more than eight LQTS genes have been identified, which when
genetically defected can lead to different forms of LQTS. Among these LQTS genes,
KCNQ] and HERG are responsible for a majority (-85-90%) of cases of inherited
LQTS, LQT1 and LQT2. Moreover, HERG protein is also a pharmacological target
fora majority of acquired LQTS as a resuit ofdrug blockade.
4.2.2 Atrfal fibrillation (AF)
11e current densities of I and I, do flot change in animal models with atrial
fibrillation (atrial tachypacing-induced)”7 Thus far, voltage-clamp data regarding I,
and in human atria have not been available24. However, several studies have
reported alterations in Ij and Ic subunits in AF patients, including decreased mRNA
expression of ERG and KCNQJ along with increased expression of minK”8”9 and
decreased ERG and minK protein expression’20.
4.2.3 Uypertrophy
In hypertrophic rat hearts, both Ic and Ic were significantly decreased,
resulting in significant prolongation of APD90 (90% repolarization)’21. In chronic
complete atrioventricular block (AVB)-induced rabbit hypertrophy model, a
prominent QT prolongation and high incidence of spontaneous TdP and sudden
cardiac death were observed, and both Ic and I, were significantly smaller in AVB
myocytes than in control’22. Xu et al. reported a significant reduction of I, density in
both Epi- and Endo- left ventricular myocytes with no significant changes in 1ic-
density, in rabbit lefi ventricular hypertrophy model94. Moreover, in AVB-induced
hypertrophic dog hearts, Volders et al. found that I, and I, had a similar voltage
dependence of activation and time course of deactivation in chronic AVB and control,
whereas I density was similar in LV myocytes but smaller in RV rnyocytes of
chronic AVB versus control, and I, densities in both LV and RV ceils were
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significantly lower in chronic AVB than control96. However, due to the variations in
species as well as the methods in creating hypertrophy animal models, some studies
showed no significant changes in IECj and Ii under hypertrophic condition, for
example, in a guinea pig model with aortic banding’23.
4.2.4 Ischemia
In a dog model of myocardial infarction, ventricular myocytes in the border
zone 5 days afier the coronary occlusion showed significantly less densities of both
Ii- and when compared with the non-infarcted region, and a significant decrease
in mRNA of dERG and dminK were also observed in the infarcted hearts with no
change of KCNQ1 mRNA’24. During the very early phase of acute ischemia and
infarction, I is increased’25”26, which might be due to the direct interaction between
lysophosphatidylcholine (LPC) and HERG’27’28.
4.3.5 Heart failure
A recent study showed that sustained tachycardia and bradycardia
downregulate ‘Ks subunits (at both mRNA and protein levels), but bradycardia also
suppresses ERG/I, causing prominent repolarization delays and spontaneous TdP.
These resuits point to a crucial role for delayed-rectifier subunit remodeling in TdP
susceptibility associated with rate-related cardiac remodeling. In a rabbit model of
tachypacing-induced heart failure, both Ic- and I were significantly down-regulated
in ventricular myocytes, accompanying a significant prolongation ofAPD’29, whereas
in tachypacing-induced heart failure dogs, only reduction of Ic density was observed
in atrial myocytes130’31. Although the resuits of different studies ofien vary, the most
consistent electrophysiological changes in the ventricles are APD prolongation,
especially at slow heart rates, with a reduction in I,, I and I, and ‘K1
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4.3.6 Diabetes
Abnormal QT prolongation in diabetic patients lias become a non-negligible
clinical problem and has attracted increasing attention from basic scientists, because
it increases the risk of lethal ventricular arrhythmias. In type-1 diabetic dog, the QTc
interval and the ventricular action potential duration were moderately prolonged,
accompanied by significant reduction in the density of Ii. No differences were
observed in the density of Ij. Western blot analysis revealed a reduced expression of
minK in diabetic dogs, while other charmel proteins were unchanged (HERG, MiRP1)
or increased (KvLQT 1)1 32 However, another recent study, using rabbit mode! of
type-1 diabetes, reported that a significant downregulation of ‘1Cr current density in
diabetic heart and rERG is severely depressed in its expression at the protein level but
not at the mRNA level’33.
4.3.7 Motecular mechanism underlying pathological changes of Ic and
(Discrepancy between mRNA and Protein)
The reduction of I andlor I under the pathological conditions described
above may provide the substrates for arrhythmias in the diseased hearts through
regional inhomogeneous prolongation ofAPD.
It is important to note that a phenomenon of disparate changes of IICj and ‘Ks
subunits expressions at protein and mRNA levels have been observed in faiing hearts,
ischemic myocardium and diabetic hearts. For example, several studies found that I
current density was significant!y diminished in myocytes from failing hearts and
diabetic hearts that are electrophysio!ogically characterized by repo!arization s!owing
and QT prolongation, despite that the mRNA !evel ofHERG was barely a!tered under
these conditions’2931”3334. Another example is shown in infarcted heart, where the
current density ofI was reduced, with no detectab!e change in KCNQJ transcripts’24.
The molecu!ar mechanism underlying this disparate expression pattem of mRNA and
protein is largely unknown and needs to be further investigated.
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5. Molecular regulation of HERG and KCNQ1 expression
Many factors, such as neural hormone, metabolic stress and medications, were
showu to regulate the expressions of HERG and KCNQ1 via the complex signaling
pathways. However, littie is known concerning their gene regulations, especially on
transcriptional and post-transcriptional levels.
5.1 Iranscriptional regulation of ion channet-encodïng genes
5.1.1 Importance and feasibility
Regulation of transcription is a complex set of events controlled by DNA
sequences positioned in proximity to the genes (promoters) and by elements acting at
a distance (enhancers). Promoters and enhancers that activate polymerase II
transcribed mRNA genes are formed by a combinatorial puzzle of short sequences
recognized by sequence-specific regulators. Generally, It is well accepted that an
ideal model systems for the study of physiologically controlled transcriptional
regulation will be monomeric proteins such as metabolic enzymes’35. Ion channels,
which are typically both heteromeric and multimeric membrane proteins, seem, at
least at the first glance, to be very unlikely a suitable candidate for transcriptional
regulation of their expression’ 90• However, large amount of recent studies showed
that, ion channel expression, either during the course of organogenesis or
pathogenesis of the heart, seems to be mediated primarily at the level of transcription
of their encoding a- or 3-subunits’37’52. Moreover, heart development is welI
govemed by a core set of evolutionarily conserved transcription factors GAlA
fami1ies’539, Mef2’60, Tbx 5161 Nkx2-5’57 and Hand2’57 which controls cardiac ccli
fates, the expression of genes encoding the contractile proteins, and the
morphogenesis of cardiac structure16265. These transcription factors also regulate
each other’s expression, forming a genetic network to program cardiac
organogenesis157. Many other transcription factors such as NFAT’66, NF-ic&67 and
C Stat3’68 have also been shown to actively participate in developing many cardiac
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diseases including hypertrophy, congenital heart failure, ischemia and etc.’ 66-174 R is
obvious that there is a missing link between the rapidly increasing knowledge of
transcription factor function and the developmental and pathological changes of ion
channel genes, prompting our further studies on detail analysis of the transcriptional
control of ion channel genes’75’77.
Specificity and precision are two most important advantages of transcriptional
regulation of gene expression, and are especially important for good control of ion
channel genes expressiofl”2 In mammalian heart, various flmctionally distinct ion
channels act in concert to maintain normal function of the heart. The functions of
these channels are either non-overlapping or only partially overlapping1”36, and, more
importantly, different ion channels have their own distinct encoding genes.
Expression of each ion channel gene can in principle be regulated independently at
the transcriptional level by recruiting of multiple different transcription factorst5778
On the other hand, transcriptional regulation can produce precisely graded levels of
gene expression’79. Notably, the precise regulation of channel expression is very
important for some channels, such as the channels contributing to the plateau phase of
the action potential, where small changes in current level can result in large changes
in the membrane potential22” so $3
5.1.2 Current progress in study of buman ion channel promoters
To date, there have been only a few studies regarding the detail analysis of ion
channel promoters in human, including SCN5A (encoding a-subunit ofhuman sodium
channel)’84, CACNA]C (also named Cavl.2, encoding a-subunit of human L-type
Ca2 channel)’85 and KCNE1 (encoding [3-subunit of human slow delayed rectifier
potassium channel)’86”87. A number of K channels have been investigated on their
genomic structures for transcriptional regulation, with their promoter regions
identified and characterized. However, a majority of these studies were conducted
with rat and mouse genes and the findings may flot be applicable to human genes,
considering large interspecies variations in the 5’-flanking regions of genes.
Research on promoter elements of human K channel pore-forming a-subunits has
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been sparse despite a recent report describing the transcriptional control of several
human KCNE genes (KCNE1 -5) encoding a family of single-transmembrane-domain
K channel -subunits that modulate the properties of several K channel a
subunits’
5.1.3 The role of stïmnlating protein 1 (SpI) in transcriptional regulation
In mammalian ceils, Spi transcription factor is an extremely versatile protein
which functions as transactivator to enhance gene transcription by direct binding to
target DNA through its zinc finger protein motifs’88”89. It was originally identifled as
the transcription factor which binds to multiple GC-boxes in the simian virus 40
(SV4O) promoter’90”9’ and the thymidine kinase (TK) promoter’92 to activate
transcription. Spi is also known to activate very large number of genes, such as
housekeeping, tissue-specific and celi cycle-regulated genes, and is required to
prevent methylation of CpG islands’93”94. Notably, one of the most important features
for Spi to exert its transactivating action is to bind to promoters which contain GC
rich elements such as GC-box (GGGGCGGGG) or GT/CACCC-box
(GGTGTGGGG)’88’89”9°’9’
5.2 Post-transcriptional regulation of ion channel genes
In addition to transcriptional regulation, several other regulatory mechanisms
are also involved in determining the ultimate level of protein expression, such as
post-transcriptional regulation, translational regulation and post-translational
modification (or protein maturation). Since my study is focusing on the gene
regulation of the ion channel genes, I will mainly discuss the post-transcriptional
regulation.
It has recently become increasingly apparent that small regulatory RNAs,
including the short interfering RNAs (siRNAs) and microRNAs (miRNAs), are also
important gene regulatory factors. MiRNAs are 22 nucleotide (nt)-long RNA
molecules which bind to partially complementary sequences within the 3’-
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untranslated region (3 ‘-UTR) of target mRNAs and suppress their translation with or
without mRNA cleavage, resulting in gene silencing’95197. Although the exact
silencing mechanism is flot well known, more and more recent evidence indicates that
miRNAs might repress gene expression by sequestering targeted mRNAs into
processing bodies (P-/GW-bodies)’98’99, where the miRNAs-bound mRNAs are
unavailable for protein synthesis but are subject to de-capping and degradation by
resident nucleases’98”99.
MiRNAs were originally identified in nematodes200, and soon thereafier ffiey
were also confirmed to exist endogenously in higher eukaryotes, including plants and
mammals’95’97’201. Most of the miRNAs are evolutionarily conserve&95197. Since the
first cloning of miRNA, une-4 miRNA, in 1993 by Lee et ai.200, miRNAs have
attracted more and more researchers’ interest in understanding the molecular details
underlying miRNA-guided gene regulation, because of their robustness in nature, and
important roles in global developmentai regulation as well as in cell differentiation
and proiiferation195’197.
More ffian 300 miRNAs have been identified to date, among winch,
microRNA-1 (miR-1) and microRNA-133 (miR-133) are known to be specificaÏly and
strongly expressed in adult cardiac and skeletai muscle and play an important role in
regulating deveiopment of the heart202’203. Whether these miRNAs are involved in
regulation of ion channel gene expression remained largely unknown.
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JHYPOTHESIS
The 5’UTRs and 3’UTRs of HERGJ and KCNQ1 genes contain important
sequence elements as the binding sites for transcription factors and miR-1/miR-133,
and interactions between these sites and transcription factors and rniR-1/miR-]33
determine the expression pattems and regional distributions of HERGJ and KCNQJ
genes and underlie the disparity between mRNA and protein expression of these
genes.
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C OBJECTIVES
The overail objectives of this study were to explore the molecular
mechanisms for transcriptional and post-transcriptional regulation of expression of
HERGJ and KCNQJ genes and to shed light on the molecular mechanisms
underlying the regional heterogeneous distributions of Ii and I and its potential
implication to arrliythmogenesis. The ultimate goal of this study is trying to develop
an efficient and practical approach to precisely control the arrhythmogenic genes
HERG1 and KCNQJ by gene interfering. To achieve this goal, the following specific
studies will be can-ied out:
1) To identify the transcription start sites in 5’UTRs of HERGJa, HERGJb, KCNQJa
and KCNQJb, and to clone and characterize their promoters as well as identify the
critical transactivators.
2) To characterize the 3’UTRs of HERGJ, KCNQJand KCNE] genes, and to evaluate
their candidature as targets for post-transcnptional repression by the muscle-specific
microRNAs, miR-1 and miR-133.
3) To define the heterogeneous expression patterns of HERG1, KCNQ1 and KCNE1
at both the mRNA and protein levels.
4) To elucidate the molecular determinants for, or the roles of transcription factors
and miR-1 and miR-133 in, the regional heterogeneities ofI1< and Iy.
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PART II.ORIGINAL CONTRIBUTIONS
CHAPTER 1.Genomic structure, transcriptional control
and tissue distribution ofHERG1 and KCNQ1 genes
In this chapter, we carried out studies mainly aiming at identification of aIl
HERGJ and KCNQJ genes’ promoter region. We performed a detailed analysis ofthe
driving elements for each gene, and we finaily targeted Spi as the essential
transactivator for ail HERG1 and KCNQJ genes by the computational method. We
also assessed the tissue distributions of ail isoforms and measured relative inter
chamber expression ofmRNA level for each gene.
This manuscript has been submitted to fEBS Letter for review in 2007.
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1.1 Abstract
The long QT syndrome genes HERG1 and KCNQI, encoding K channels critical
to cardiac repolarization, are both comprised oftwo isoforms: HERGJa and HERGJb,
and KCNQJa and KCNQJb, respectively. Expression ofthese genes is dynamic
depending on differentiation status and disease states. Here we identitled their core
promoter regions and transcription start sites. We obtained the data pointing to the
potential role of Spi in transactivating these genes. We compared expression
profihing ofthese genes across a variety of human tissues and demonstrated
unexpectedly widespread tissue distributions of ail the transcnpts. We further
revealed that the mRNA levels of ail HERG1 and KCNQ1 isoforms are
asymmetrically distributed within the heart, being predominant in the right relative to
the Ieft chambers. Our study provides highly valuable imowiedge ofcore elements
related to transcriptional regulation and identifies targets for studies of genetic
variants in diseases associated with the HERGJ and KCNQJ genes.
Keywords: Potassium channels; Promoter; Transcription; HERGJa; HERG1b;
KCNQ]a; KCNQJb; Spi
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1.2 Introduction
To date, no less than eight long QT syndrome (LQTS) genes have been isolated,
which when genetically defected (loss-of-function mutations) can lead to different
forms of LQTS. Among these LQTS genes, KvLQT1 (KCNQ1 or Kv7.1) and human
either-a-go-go-related gene (HERGJ or KCNH2) are responsible for a majority (85-
90%) of cases ofinherited LQTS. Moreover, HERG1 protein is also a
pharmacological target for a mai ority of acquired LQTS as a resuit of drug blockade.
HERGJ encodes the pore-forming Œ-subunit ofa K channel with biophysical and
pharrnacological properties similar to those ofrapid delayed rectifier K current (kr),
a critical repolarizing current in cardiac celis [1]. In mammalian heart, two HERGJ
transcripts (we term the long isoform HERGJa and the short isoform HERG1b),
encode proteins differing in their amino-terminal sequence and gating properties [2-6].
A recent study proposed that cardiac I channels are minimally composed of
HERG1a and HERG1b Œ-subunits that co-assemble in the membrane [5]. On the
other hand, KCNQ1 encodes the pore-forming Œ-suburnt of the K channel
underlying slow delayed rectifier K current (I), another cntical repolarizing current
in cardiomyocytes [7]. Jntriguingly, KCNQJ also is composed oftwo isoforms
differing in their N-termini: isoform 2, encoding transiational start in the middle of
membrane segment 1 [8-10]. When expressed in a heterologous context, the isoforrn
2 protein functions as a dominant negative isoform [8]. For convenience, here we
designate the two isoforms KCNQ]a (long isoform or isoform 1) and KCNQ]b (short
isoform or isoform 2).
Strikingly, expression ofboth HERG1 and KCNQJ genes is dynamic
depending on differentiation status and cell cycle ofthe celis, contributing
importantly to the developmental evolution ofmyocardial action potential
morphology. For example, I is the sole component of delayed rectifier K current in
fetal day 18 mouse ventricles, yet both Ic and I are observed on postnatal day 1. By
day 3, I is the dominant component. With further development into adulthood,
neither Ic nor ‘Ks is obsened [11,12]. With respect to canine heart, it was found that
I is absent or minimal before age 4 weeks, at which time Ig is the major
C repolarizing current [12]. With progression toward adulthood, Ic appears and
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increases in density while I density diminishes. Moreover, when the aduit cardiac
celis become dedifferentiated or cancerous, sucli as AI-1 and HL- 1 (murine atrial
tumor ceil unes) celis, Ic regains its predominance among the expressed K channels
[13,14]. While in tissues other than heart and brain there is restricted HERGJ
expression under normal situations, tumor celis ofvarious histological origins
overexpress the HERGJa and HERGJb genes and their protein products [15-20]. It
appears that expressions ofHERG1 and KCNQJ genes are tightly controlled by
certain factors according to a defined genetic program related to morphogenesis
during development. Understanding the transcriptional control ofthese genes is
therefore necessary.
The objective of this study was two fold: (1) to elucidate the genomic structure
and promoter regions ofHERGJ and KCNQJ genes and (2) to map the distribution of
HERGJ and KCNQJ transcripts in multiple human tissues and in various regions of
the heart. Our study defined the transcription start sites and 5’ flanking genomic
sequences of each isoform and delineated critical genomic elements necessary for
transcriptional control of the genes. Our data demonstrated tissue-dependent
distributions of the transcripts and revealed regional differences of expressions of
these isoforms within cardiac tissues. The findings shed light on the molecular
mechanisms for transcriptional control of these genes and enable future work to
determine factors responsible for tissue-specific expression.
1.3 Results
1.3.1 Identification of the transcription start sites of the HERGJ and KCNQJ
genes
The HERGJ genes refer to two different variants that diverge at the N terminus,
HERGJa (HERG) and HERG]b. As documented in our previous studies [21],
HERGJa contains a single transcription start site (TSS, designated +1) Ïocated to 79
bp upstream from the translation start codon (ATG) ofHERG]a 5’-UTR (Fig. lA,
GenBank accession DQ120124). For HERGJb, 5’RACE identified one major
fragment of 403 bp upstream ATG, along with two minor fragments with sizes of 150
C bp and 296 bp, respectively, in the 5’-UTR of HERGIb (Supplemental Figure 1).
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Sequencing ofthese fragments indicated the 403-bp and 296-bp bands represent two
separate T$Ss ofHERG]b. The potential TSSs of HERGJb described above were
verified by RNase protection assay using RNA samples from human heart
(Supplemental Figure 1). The major fragment of400-bp length corresponding to the
larger TSS obtained by 5 ‘RACE was identified along with a weak band of around
300-bp size. These resuits defined two principal TSSs in HERG1b: the larger (the
most upstream) TS$ revealed by 5’RACE is likely the major form ofHERGJb
transcripts in human heart and the minor TSS represents a relatively rare form of
HERGJb transcripts (Fig. lB, GenBank accession DQ120125).
Similar to the HERGJ genes, the KCNQJ genes are also composed oftwo
isoforms, the long isoform KCNQJa and the short isoform KCNQ]b that also differ in
their N-termini. 5’RACE was used to obtain the 5’ends ofKCNOla and KCNQ1b
transcripts. For KCNOJa, the nested primer (the second reverse primer) was designed
from the very end ofthe N-terminus of KCNQJa because this region is tmique to
KCNQJa and is absent in KCNQ]b. The expenment using RNA samples from human
heart yielded two discrete fragments. Sequence analysis suggests that the two
fragments represent separate transcription start sites: TSSI (designated +1) and TSS2
(josition +12) which are located to 80 bp and 6$ bp, respectively, upstream ofthe
translation start codon (ATG) ofKCNQ]a gene (Fig. 1 C, Genbank accession
EF010934). For KCNQ1b, 5’RACE identified a single discrete fragment of—400 bp
size. Sequencing analysis indicates that the fragment spans a portion ofthe first intron
ofKCNQJ genomic DNA and a portion ofKCNQJb N-terminus (Fig. 1D, Genbank
accession EFO 10935). The TSS ofKCNQ]b was defined to 274 bp upstream ofthe
translation start codon (ATG) ofKCNQ]b.
1.3.2 Genomic arrangement of the HERGJ and KCNQ1 genes and their
promoter regions
Figure 2 provides a schematic view ofgenomic arrangement ofHERG genes with
HERGJa, HERGJb, HERG2 and HEEG3 aligned for comparisons. Based on the
resuits described above, it is clear that HERG]a promoter is localized to the 5’-
flanking region of the HERGJa gene and the HERGJb prornoter falis within the
intron 5 ofthe HERG genomic DNA. The genomic exon 6 corresponds to the N-
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terminus of HERG1b, whereas HERGJa uses the genomic exon 6 as a part ofits
intron that spans genomic intron 5, exon 6 and intron 6. As such, HERG]b uses the
downstream 403-bp region ofthe intron 5 as its 5’-UTR and the 250-hp region
upstream the TSSs as its core promoter sequence.
Genomic analysis indicates that the promoter sequence ofKCNQJa fails mto the
5’-flanldng region ofthe KCNQJ gene. KCNQJb uses a portion ofintron 1 ofthe
KCNQJ genomic DNA as its promoter region, and its TSS and translation start codon
(ATG) plus the next two nucleotides both fali within the intron 1 region (Fig. 3).
1.3.3 Structura] analysis of the 5’-flanking regions of the HERG1 and KCNQJ
genes
Computer analysis of3000-bp 5’-flanking regions ofHERGJ and KCNQ1 using
the Matlnspector program revealed that none ofthem contains canonical mammalian
TATA box within 1 kb upstream oftheir TSSs. They also lack other known common
promoter elements that are required for transcription initiation complex, including the
initiator element, the downstream promoter element (DPE), or the TFIffi recognition
element (BRE). Less common promoter elements such as the downstream core
element (DCE) and the multiple start site element downstream (MED- 1) are also
missing. There is one putative CCAAT site in HERGJa 5’flanking region, which is
absent in the HERGJb promoter sequence. KCNQJb has five CCAAT boxes, but
KCNQJa has none. However, among these five CCAAT consensus sites, only one is
located within the core promoter region (-33) and others are at least 2.3 kb away from
theTSS.
Cis-elements for the heart-specific GATA4 as the potent transactivator in cardiac
celis is absent in the 5’-flanking regions ofthe HERGJ and KCNQJ genes. Consensus
sites for other members of the GATA family were identified. The distal 5 ‘-flanking
region of HERGIb contains two putative GATAI binding sites (-62$ and -1431) and
one GATA3 binding site (-1446). The KCNQJa 5’-flanking region contains three
GATA1 consensus sites located distal to its TSS1 (1.4 kb, 1.6 kb and 2.0 kb
upstream). KCNQ]b contains two GAlA 1 sites with one at 50 bp and the other at 1.5
kb upstream its TSSs. The cardiac-specific homeobox Nkx2.5 was found in none of
the genes. Cis-elements for other TFs important to cardiac development and function,
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including serum responsive factor (SRF), Hand2 and MyoD, were found in the 5 -
flanking regions ofHERG] and KCNQJ genes (Table 1).
1.3.4 Characterizatïon of the promoter regions of the HERG1 and KCNQ1 genes
To assess the functional role ofthe 5’-flanking regions ofHERG] and KCNQ] in
the transcriptional regulation of these genes, various lengths of putative promoter
fragment-luciferase constructs were generated and tested for their ability to drive
expression ofthe reporter gene in a rat ventricular celi une (H9c2) and a human
embryonic lddney ceil lime (HEK293).
The core promoter of the HERGJa gene was defined to 487-bp which showed a
maximum luciferase activity >8 folds the activity of the promoter-less vector (PGL3-
basic) (Fig. 4A). for HERG]b, the +851+191 fragment demonstrated small but
statistically significant luciferase activities. This fragment is contained within the 5’-
UTR ofthe T$S1 variant but is in the proximal promoter region ofthe TSS2 isoform.
Significant luciferase activity was obtained with a longer fragment (-60/+19 1),
indicating that the basal promoter activity is contained in the very proximal 5’-
flanldng region (i.e. the first 60 bp upstream ofTSS1). The maximum activity was
reported by -2501+191, -390/+191 and -595/+191 constructs, suggesting that -
250/+191 fragment contains the core promoter sequence of HERG]b (fig. 4B).
KCNQ1a promoter constmcts had approximately 10—15 times the activity of the
promoterless vector (pGL3 basic) and 50% ofthe promoter activity of the pGL3
construct that contains both the SV4O promoter and enhancer (pGL3 control, data flot
shown). The overali transcription activities of different KCNQ]a promoter constructs
were similar in ail three celi unes and consistently, the -329/+60 fragment elicited the
maximum promoter activities (Fig. SA). The core promoter of the KCNQ1a gene was
thus defined to -3297+60. for KCNO]b, though a statisticaily significant iuciferase
activity was seen with a -117/+71 fragment relative to promoter-free PGL3 -vector,
more robust activities were consistently obsenred with longer fragments (Fig. 5B).
for example, in both H9c2 and HEK293 celis, luciferase activities increased by
around 15-fold with the vector containing -13367+71 fragment ofthe KCNQ]b
promoter.
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1.3.5 Multiple Spi cis-elements and CpG islands in HERGJ and KCNQ1a core
promoter regions
0fparticular note is the high GC content ofthe core promoter regions of
HERGJa, HERG1b and KCNQ]a. The high GC content confers three important
features to these genes. First, HERGJa, HERG1b and KCNO]a ail contain multiple
Spi consensus sequences within their core promoter regions: -224, -366, -380 and -
428 loci for HERGJa (Table 2), +118, +54, +26, -17 and -116 loci for HERGJb
(relative to TSS1 in Fig. 4D), and -61, -114, -134, -190, -259, -277, -295, -347, -407,
and -460 for KCNQJa. By comparison, though there are seven putative Spi binding
sites within 3-kb length ofKCNQ]b 5’flanking region, only one site is proximai to its
TSS (at position -15) and the other six sites are around 1-kb distal to its TSS.
Strildngly, the positions of Spi clusters correspond well to the fragments that
demonstrated significant promoter activities, as shown in fig. 4 and fig. 5. for
example, the -487/+4 fragment that contains a cluster of four Spi sites in HERGJa
showed the maximum promoter activity, and similar situations were seen with
HERGJb and KCNQJa. For KCNQ]b, the minimal promoter activity corresponded
roughly to the presence ofa single Spi site proximal to the TSS and the greatest
promoter activity was coincident with the -1336/+71 fragment containing a cluster of
three Spi elements.
The second feature of a GC-rich promoter is ofien the presence of so-called CpG
islands [22,23], clusters ofGC dinucleotides near the TSS. Using the CpG Island
Searcher (http://www.cpgislands.com) [24], we made prediction of CpG islands in
the promoter regions (500 bp upstream TSSs) of HERGJa, HERG]b and KCNQ]a
and we identified two CpG islands in HERG1a and KCNQ]a and three in HERG1b
(Fig. 6).
Another important feature associated with Spi -rich promoters is the presence of
GAGA boxes around the Spi elements [25,26]. We identified a total of seven GAGA
boxes within 3-kb 5’-flanking region of KCNOIb, among which four are in a cluster
within the -1336/+7 1 fragment. By comparison, there is no GAGA box in the
KCNQJa 5’-flanking region, and there is only one in each HERGJa and HERG1b
promoter regions.
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1.3.6 Expression and tissue distribution ofHERG1 and KCNQ1 genes
Expression ofHERGJ and KCNQJ genes was assessed from two aspects. First,
the relative abundance of transcripts was determined by TaqMan real-time RT-PCR
with RNA samples extracted from various human tissues. We found that the heart
was the organ expressing an incomparably high level HERG1a; the mRNA level of
HERGJa was found to be >100 times higher in heart than in other tissues except for
brain where HERGJa mRNA levels was some 30% ofthe heart level (Fig. 7A).
HERG1b transcripts were found to be most abundant in pancreas and colon, then in
heart, kidney and lung (Fig. 7A). Surprisingly, the heart was one ofthe organs that
express the lowest level ofKCNQJa (Fig. 7B); similar to HERGJb, KCNQ1a
demonstrated the most abundant expression in pancreas, colon, kidney and lung.
KCNQJb predominantly expressed in heart and pancreas (Fig. 73).
Second, we compared the relative abundance oftranscripts across the four
chambers of the human heart: lefi ventricle (LV), right ventricle (RV), lefi atrium
(LA) and right atrium (RA). The resuits in Fig. 7C and 7D revealed that the four
genes have a similar pattem of expression with significant intervenfricular and
interatrial gradients ofmRNA concentrations: RV>LV and RA>LA. And the regional
differences of the four mRNAs were within the same range. There were no atrial
ventricular differences of expression.
1.4 Discussion
K channels are represented by an extremely large and varied superfamily of
genes including pore-forming a-subunits and regulatory auxiliary 13-subunits. Many
of these channels undergo remodeling processes, mostly with alteration in gene
expression, during pathogenesis and disease progression. A number ofK channels
have been investigated on their genomic structures, with their promoter regions
identified and characterized. However, a majority of these studies were conducted
with rat and mouse genes and the findings may or may flot be applicable to human
genes considering large interspecies variations in the 5’-flanking regions ofgenes.
Research on promoter elements ofhuman K channel pore-forming a-subunits lias
been sparse despite that a recent report that described the transcriptional control of
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several human KCNE genes (KCNE 1-5) encoding a family of singie-transmembrane
domain K channel -subunits that modulate the properties of several K channel a
subunits [27]. HERGJ and KCNQ] genes encode K channel Œ-subumts that
critically determine repolarization rate and repolarization resewe in cardiac celis
thereby the likelihood of arrhythmias. Expression levels of these genes define the
functional capacity of their gene products, I and I, which manifests in the course
ofearly development ofheart and during pathogenesis with dramatically aitered gene
expression. Elucidation ofthe promoter elements and transcriptionai control ofthese
genes is therefore a necessary step towards understanding the functional adaptation
and impairment during developmental stages and pathological processes associated
with electrical remodeling.
1.4.1 Transcriptional control ofHERGJ and KCNQJ genes
HERG1a and HERG]b have been believed to be altematively spiice variants of
the same gene, so are KCNQ]a and KCNQJb [3,4]. The present study does flot
support this notion; instead, our data suggest that they ail represent independent
transcripts because they each have their own transcription start sites and their own
promoter regions.
Regulation of transcription is a complex set ofevents controlled by DNA
sequences positioned in proximity to the genes (promoters) and by elements acting at
a distance (enhancers). Promoters and enhancers that activate polymerase II
transcribed mRNA genes are fonned by a combinatoriai puzzle of short sequences
recognized by sequence-specific regulators.
One common feature ofthe promoter regions ofHERG] and KCNQ] genes is
GC rich; there exist multiple Spi consensus binding sites in the proximal promoter
regions (>5 sites) of HERGJa, HERG1b and KCNQ]a genes and in the 5’-flanking
region of KCNQ]b. Spi is a widely distributed member ofa multigene family of
zinc-finger transcription factors that bind DNA in mammalian celis primariÏy via
interaction with GC-box elements [28-31]. The binding of Spi to GC-boxes is ofien
critical to achieving significant leveis of transcription from TATA-iess promoters and
is intimately involved in the determination of the transcription start site(s). Our
previous studies have confirmed the role of Spi as a transactivator ofHERG]a [21].
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For KCNQJb, there is one putative Spi site and one CCAAT box within its core
promoter region, and there six more Spi sites and 4 more CCAAT boxes distal to the
TSS within 3-kb frame ofthe 5’-flanldng region. Protein binding to CCAAT boxes
can activate gene transcription [32-34]. It is possible that the Spi and CCAAT within
the promoter region cooperate to transactivate KCNQ1b and the distal Spi and
CCAAT sites act as enhancers of KCNQ1b transcription. Our data therefore suggest
that HERGJ and KCNQJ genes are controlled by Spi for their transcription activation.
Altematively, the cluster of GAGA boxes, which exist only in KCNQJb but flot in
KCNQ]a and HERGJa/HERG1b, may play a role in a positively cooperative way to
enhance the as it has been documented that the GAGA factor acts as transcriptional
coactivator/potentiator of Spi [25].
Another property of HERGJa, HERG1b and KCNQJa promoters is the presence
of CpG islands (clusters of CpG dinucleotides) near their TSSs. CpG islands often
reside in the promoter region of genes, and the methylation of CpGs in these regions
is thought to affect the expression oftheir downstream genes [22,23]. Whether the
CpG islands play a role in regulating the activities ofHERGJa, HERGJb and
KCNQJa promoters is worthy ofdetailed studies considenng that the expression
levels ofthese genes can have great impact on cardiac repolarization thereby the
likelihood of arrhythmias.
1.4.2 Expression profiles ofHERG1 and KCNQJ genes
Consistent with the general lack of cis-elements for cardiac-specific traiscription
factors in the core promoter regions of HERGJa/HERG]b and KCNQ]a/KCNQ]b
genes, the transcripts demonstrated widespread distribution across of a variety of
human tissues. This could be explained by presence of multiple sites for ubiquitous
Spi or of CCAAT box. Prominently, the ion channel gene promoters that have been
identified to date, regardless of animal species from which they are from, share some
general structural features common to the housekeeping-type promoters. That is, the
promoters lack consensus TATA boxes and are GC-rich with multiple putative Spi
consensus elements. However, it is also evident that there are clear tissue preferences
of expression for each of the isoforms. For example, most ofthe transcripts were
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C found abundantly expressed in pancreas, heart, colon and lung, but rarely in skeletal
muscle, liver and breast. Intriguingly, among the four transcripts, HERG1a and
KCNQ]b were predominantly expressed in heart. This is in une with the fact that they
both contain five putative cis-elements for the cardiac-specific transcription factor
Hand2, while HERGJb and KCNQJa do not.
Our study revealed regional differences or inter-chamber gradients of expression
ofHERG] and KCNQ] genes. Strikingly, ail four isoforms demonstrated the same
interventricular and interatrial gradients: RV>LV and RA>LA. The finding provides
an explanation for the known interventricular gradients ofIj and Ii currents and of
cardiac repolarization as well [35,36]. It has been well documented that the current
densities of Ic and Iici both are larger in RV than in LV and accordingly, action
potential duration (APD) is generally shorter in RV than in LV. This difference may
5e ofphysiological importance against arrhythmogenesis under normal conditions.
However, when exacerbated under abnormai or pathological conditions, the
repolarization heterogeneity becomes a substrate or prerequisite for arrhythmias to
occur and to sustain (such as torsade de pointes). Our previous studies revealed that
Spi level is higher in RV than in LV [37]. This may account for the interventricular
gradients ofHERGJ and KCNQ] subunits. Future studies are required to clarify
whether the interventricular inhomogeneity of expressions of these genes contributes
to arrhythmogenesis.
It should be noted that the roies ofHERGJb and KCNQJb in forming Ig and Iy
and their exact relationships to HERGJa and KCNQJa, respectively, are to be better
defined. It has been claimed that the cardiac I channels mimmaliy comprise
HERG1a and HERG1b subunits, implying that HERG1b co-assemble with HERG1a
to form the complete HERG channels [2,5]. Based on the available data, KCNQ15 is
a negative dominant isofonn that co-assembles with KCNQ la to dampen the function
ofthe latter [8-101. Based on these available data, the present study would suggest
that the same mechanisms oftransactivation between HERGJa and HERGJb should
produce a positively cooperative effect on I function, whereas the same mechanisms
oftransactivation between KCNQJa and KCNQJb should produce a negative
feedback effect on I function, at the gene transcription level.
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( In summary, we have identifled the core promoter regions and the
transcription start sites ofHERGJa, HERG1b, KCNQ]a and KCNQ1b genes. We
compared relative expression pattems ofthese genes across a variety ofhuman
tissues and demonstrated unexpectedly widespread tissue distributions of ail the
transcripts in addition to heart where the genes were originally cloned. Our data
further reveaied that the mRNA ievels of all HERGJ and KCNQ] isoforms are
asymmetrically distributed within the heart, being predominant in the right chambers
relative to the lefi ones. This flnding may heip us understand the molecular
mechanisms for arrhytbmogenesis since heterogeneity of ion channei activities is an
important substrate for arrhythmia to occur. Our study therefore provides highly
valuable knowledge of core elements related to transcriptional regulation and
identifies targets for studies of genetic variants in diseases associated with the
HERG1 and KCNQJ genes.
1.5 Materials and methods
1.5.1 Rapid amplification of cDNA ends (5’RACE)
The transcription start sites (T$$s) of HERG1b, KCNQ1a and KCNQJb genes were
determined with Ambion’s RNA—Ready cDNA Human Heart RNA iigase-mediated
5’RACE kit, as previously described [21]. Human ventricular RNA sample was
purchased from Clontech. The gene specific primers (GSP) were designed based on
the human HERGJb sequence (Genbank accession: NM_l 72057) and the GSP1 was
5’-CTTCCGTCTCCTTCAGCAGG-3’ and the GSP2 (nested) was 5’-
ATGCAGGATGGTCCAGCGGT-3’, corresponding to 597-616 bp and 491-510 bp,
respectively. For KCNQ1a (GenBank accession: NM 000218), the primers used for
5’RACE were GSP1: 5’-AGGAAGACGGCGAAGTGGTA-3’ and GSP2: 5’-
CGCGTGCTGTAGATGGAGAC-3’. For KCNOJb (GenBank accession:
NM 18 1798.1), The GSP1 was ACGTACTCCGTCCCGAAGAA and GSP2 was
CACGATGAGGTCGATGATGG.
1.5.2 RNase protection assay RPA)
To determine the exact TSSs ofthe HERGJ genes, we hybridized 30 tg of total
RNA from human hearts (Clontech) with a human genomic antisense riboprobes in a
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C solution hybridizationfRNase protection assay [2 1,381. For HERGJb, a human
genomic antisense riboprobe (1000 bp) corresponding to the down stream 900 bp of
intron 5 and upper stream 100 bp of exon 6 of the HERG1 genomic sequence
(NM_1 72057) was used. The fragment was PCR synthesized and cloned to pGEMT
easy vector for preparation ofRNA probes. RNA probes were synthesized using in
vitro transcription kits (Ambion). RNase protection assays (RPAs) were performed
according to the HybSpeed RPA (Ambion) protocois. Yeast tRNA (20 .tg) was used
as a negative control to test for the presence of probe self-protection bands.
1.5.3 PCR amplification of putative promoter regions and construction of
promoter-luciferase fusion plasmids
A series of fragments ofvarying length inciuding the TSSs ofHERG1 and
KCNQ] promoters were ampiified with human genomic DNA the Homo Sapiens
bacteriai artificial chromosome (BAC) clone RP1 1-166D23 (accession No.
AC011234) for HERGJ and RP5-915F1 (accession No. AC124057) for KCNQ]
genes as templates using specific primers and PCR Advantage and Advantage-GC
genomic polymerase mixes (Clontech K-1905-Y). PCR products were subcloned into
luciferase-containing PGL3-Basic (Promega) vector. The integrity and orientation of
ail constructs were confirmed by restriction endonuclease anaiysis and DNA
sequencing.
1.5.4 Ceil culture
The celi unes used in this study were ail purchased from American Type Culture
Collection (ATCC, Manassas, VA). H9c2 (rat ventricuiar celi une) and HEK293
(human embryonic kidney ceil une) were cultured in Duibecco’s Modified Eagle
Medium (DMEM).’7 SKBr3 (human breast cancer ceii une) celis were maintained in
McCoy’s 5A Modified Medium and LNCaP (human prostate cancer cell line) in
RPMI 1640 medium. The cultures were ail suppiemented with 10% fetal bovine
serum and 100 pg!mi penicillinlstreptomycin. The non-cardiac cdl unes were used to
serve as comparison for H9c2 cardiac ceils. SKBr3 has been shown to express
endogenous HERG1 proteins [17], and HEK293 and LNCaP do not express
functional HERG1 proteins [39].
1.5.5 Transfection and luciferase assay
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Ceils (1 X 1 05/well) were transfected with 1 .tg PGL3—target DNA (firefly
luciferase vector) and 0.1 j.tg PRL-TK (TK-driven Renilla luciferase expression
vector) with lipofectamine 2000 (Invitrogen). Following transfection (48 h),
luciferase activities were measured with a dual luciferase reporter assay kit (Promega)
on a luminometer (Lumat LB9507) [21,37].
1.5.6 Real-time RI-PCR
The mRNA samples from various human tissues were purchased from Ambion.
TaqMan quantitative assay oftranscripts was performed with real-time two-step
reverse transcription PCR (GeneAmp 5700, PE Biosystems), involving an initial
reverse transcription with random primers and subsequent PCR amplification ofthe
targets [21,37]. Master RI reaction mix 50 j.tl (containing lOx reverse transcription
buffer 10 !d, 25x dNTPs 4 j.il, lOx random primers 10 tl, MultiScribeTM Reverse
Transcriptase (50 U/j.d) 5 fil, and nuclease-free H20 21 j.fl) and 50 j.il ofRNA sample
(10 fig) were mixed into a PCR reaction tube. The reaction was carried out at 25°C
for 10 min and 37°C for 120 min to obtain the first strand cDNAs. Master PCR
reaction mix 23 jil (including 2x TaqMan universal PCR master mix 12.5 jil, 20x
assay mix 0.63 pi, H20 9.9 pi) and 2 pi ofthe first strand cDNA sample were
pipetted into 96-well plate and centrifuged at 2000 rpm for 2 min at 4°C. The
amplification reaction was set as follow: 50°C for 2 min and 95°C for 10 mm,
followed by 15 s at 95°C and 1 min at 60°C for 40 cycles. Human GAPDH control
reagents (Applied Biosystems) were used as intemal controls. We used the
comparative cycling method (z\C) to quantify the level oftarget transcripts
(GeneAmp 5700 sequence detection system). AC values were calculated as: AC
CTarget
— CGApDH and AAC = ACg
— ACNC, where C indicates the number of cycles
for amplification of target transcripts (CTarget) or GAPDH (CGAPDH), ACDg represents
the AC obtained from RNA samples treated with drugs the AC from RNA samples
without dmg treatment. Finally, the amount of target transcription, normalized to an
endogenous reference GAPDH and relative to control, was calculated by
1.5.7 Data analysis
Group data are expressed as mean ± S.E. Statistical comparisons (performed
using ANOVA followed by Dunnett’s method) were carried out using Microsoft
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C Excel. A two-tailedp<0.05 was taken to indicate a statistically significant difference.
Nonlinear least square curve fitting was performed with CLAMPFIT in pCLAMP 8.0
or GraphPad Prism. Cis-elements for transcription factor binding sites were analyzed
with Matlnspector V2.2.
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1.8 Figures and Figure Legends
Figure 1. Identification of transcription start sites ofHERG] and KCNQJ genes.
Shown are the 5’-fianldng regions containing the core promoter
sequences ofthe HERGJa (A, Genbank accession No.: DQ120124),
HERGJb (B, Genbank accession No.: DQ120125), KCNQ1a (C,
Genbank accession No.: FF010934), and KCNQ]b (D, Genbank
accession No.: EF010935) genes. Transcription start sites (TSS5) are
indicated by backward arrows and designated position +1. The consensus
binding sequences for Spi transcription factor (IF) or other TFs are
underlined and the core sequences of the Spi cis-elements or other
elements are bold. for convenience, the positions of consensus sites are
indicated by the numbers within the brackets, which were counted by the
first nucleotides of the consensus core sequences relative to TSS (+ 1).
Figure 2. Genomic structure ofHERG gene subfamily. (A) The genomic
arrangements ofHERG gene subfamily members including HERG1a,
HERG]b, HERG2 and HERG3 are aligned against the HERG genomic
DNA. The first seven exons and introns in the HERG genomic DNA are
labeled by arrows and numbers. (B) Schematic illustration ofifie
relationships between the promoter regions (dashed unes) ofHERG]a
and HERGJb and the HERG genomic DNA.
Figure 3. Genomic structure ofKCNQJ gene subfamily. Schematic illustration of
the genomic arrangements ofKCNQJ gene subfamily members KCNQJa
and KCNQ]b are aligned against the KCNQJ genomic DNA, showing
the relationships between the promoter regions (dashed unes) of
KCNQIa and KCNQJb and the KCNQ genomic DNA. Note that the TSS
(transcription start site) and exon 1 of KCNQIb falis into the intron 1 of
KCNQ1a.
Figure 4. Analysis ofthe HERGJa (A) and HERGJb (B) promoter activities in
various ceil lines including H9c2 rat ventricular ceils, LNCaP human
prostate cancer ceils, and HEK293 human embryonic kidney celis. A
schematic representation ofthe 5’ deletion constructs ofthe HERG1a or
L.,
O.)
HERG]b promoter region is shown in the left panels. Nucleotides of,
fusion plasmids are numbered with respect to the T$S (+1) identified by
5 ‘RACE. Firefly luciferase expression levels were divided by co
expressed Renilla luciferase activity and expressed as relative activity
divided by the promoter-less construct (PGL3-Basic). The experiments
were performed in duplicate for each experiment and the number (n) of
experiments is indicated by the values within the brackets.
Figure 5. Analysis ofthe KCNQIa (A) and KCNQJb (B) promoter activities in
H9c2 rat ventricular ceil une and HEK293 human lddney embryonic ceil
une. A schematic representation of the 5’ deletion constructs of the
KCNQ]a or KCNQ1b promoter region is shown in the left panels.
Nucleotides of fusion plasmids are numbered with respect to the TSS (+1)
identified by 5 ‘RACE. Firefly luciferase expression levels were divided
by co-expressed Renilla luciferase activity and expressed as relative
activity divided by the promoter-less construct (PGL3-Basic). The
experiments were performed in duplicate for each experiment and the
number (n) of experiments is indicated by the values within the brackets.
Figure 6. CpG islands ofHERGJ and KCNQ1 genes predicted using the CpG
Island Searcher (http://www.cygisIands.com) [24]. The criteria for
inclusion as CpG islands were %GC=55, observed CpG/ expected CpG
(obsCpG/expCpG)=O.65, nucleotide length=200 bp. Xxx. for HERGJa,
CpG island 1: %GC=67.3, obsCpGlexpCpG=0.655, length=l 50; CpG
island 2: %GC=74.4, obsCpG/expCpG=O.878, length=907. for HERG]b,
CpG island 1: %GC=67.6, obsCpG/expCpG=0.924, length=855; CpG
island 2: %GC=60.4, obsCpG/expCpG=O.652, length=268; CpG island 3:
%GC=7 8.2, obsCpG/expCpG0.654, length=23 8. for KC’NQJ a, CpG
island 1: %GC=59.7, obsCpG/expCpG=0.708, length=647; CpG island 2:
%GC=74.2, obsCpG/expCpG=0.796, length=399. Note there are no CpG
islands in 5’-flanking region ofKCNQ]b gene.
Figure 7. Distribution ofHERG1 and KCNQ1 transcripts in human tissues and
regional differences of expression in the heart. (A) and (B) Relative
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levels ofHERGJa/HERGJb and KCNQJa/KCNO1b mRNAs,
respectively, in various tissues indicated, showing the tissue distribution
ofthe transcripts. The concentrations ofmRNAs were determined by
quantitative real-time RT-PCR. The data were normalized to the value in
skeletal muscle. The mRNA levels in heart represent averaged
concentrations of four different chambers: lefi ventricle (LV), right
ventricle (RV), lefi atrium (LA) and right atrium (RA). (C) and (D)
Relative levels ofHERG1a/HERGÏb and KCNQJa/KCNQ]b mRNAs,
respectively, in four different chambers of the heart, showing the regional
difference of expression in the heart. *p<o.05 vs. LV or LA; +p<O.05 vs.
HERG1a or KCNQ]a.
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A HERGIa
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-150 GGA3ccAGGAGTccGGecTcGGGcGGGcGAGCGcAGcGcc-G3c-ACGC3
Spi (-224)
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-53 CC(3CGCCCGTGCTCGCCTTC-GCCGCGGGGIGCGGG3ACCACGGC CCGCC
-1
tTSS (+1)
-31 CCCGCCCGGCOCGCCCATC-GGCTCAGGATG
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B HERGIb
-300 CCACCTGAGCCCCTGGCATCTGCCCTGCTCCTGTGCOCGCTGCA%’GTGCC
-250 CGTGAGITGCGGTGGGTCTGTGCATGTGCC3CCTGTATGTc4TCGGCA3GCG
-200 TGTGTGTTCCTGCCAGTCACTAGCAGTCTCTCCATCTCTGGGTGTCTCIG
-150 TCTGACTCTGGCTGGCTCAGCACTGGACCGGCTÇ4GQCGGGGGTGTCAGGG
Spi (-116)
-100 AGACCATTAATCTGCGGTGACAGGCCCGGCTGCTGGO3!3AGGGGGAGGG
-50 CTCAGGCIGCCGGAGCGCCGCTGCAGGA3CCTGGGCGG3CTGCGGGGAG
Spi (-17)
+ 1 GCGGCCGCTGGCTGGGCACCGGCGGGGCGGGGGAGCCTAGTGTGGCGGGG
1TSS1 (+1) Spi (+26)
+51 T
SpI (+54)
± 101 CCGAGTGCGCCCGCTGCTGGGCTGGCGGGCGGGCAGAGCACGGCACCCEG
TSS2 (+10f) Spi (+118)
+ 151 GCAGCAGGGCCCACGCCACGGGGCCAT0-GGCAGCTCGAGCCAGGCA3GC
+201 GCTGCÇCACGCTTAÇTGCCAGGGTGACCCCAGCCCTG33CCCAGACA
+251 ACCACCCTGGCTTCATGCCAGGGGCTGCTOTGGTTGCCAGTCGGCOAGCC
+301 TCGGGGGTGCAGCÇTGGGCTGGGACTGCT3CTGGGGTGCAGGTGAGGCAG
+351 TG3CCGGGCCCTCAGGCCCCAGGGÇAGGCAGGCTGCAO-GGAGCCAAGTCC
÷4 1 CCATG
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O C KCNQIa
-538 AGGCAGAGCAGGCGGGCATCAGAAGTGGGGGCCAAGCAGGTGGGTGAGGC
-428 CAGGGCAGGAGCAAGÇAGGGGAGATGCAGACGGGGCGGGGCCAAGCAGGT
Spi (-460)
-438 GGGTGAGGGCGGGGCCAAGCAGGTGGGCGGGGAGGGGGCGGGGCCAGGCG
Spi (-407)
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C Table 1. Number of consensus binding sites for cardiac-specific or -related
transcription factors within a 3-kb frame of the 5’-flanking regions
ofHERG1 andKCNQJ genes
5’-Flankïng
Hand2 SRF MyoD GATA4 Nkx2.5
Region Me12
HERG1a 5 4 3 0 0 0
HERG1b 0 5 3 0 0 0
KCNQJa O 0 5 0 0 0
KCNQ1b 5 $ 5 0 0 0
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Table 2. Number of consensus binding sites for stimulating protein 1 (Spi)
and CCAAT boxes wïthin the core promoter regions and CpG
islands within a 3-kb frame upstream the trans]ational start sites
(TSSs) ofHERG1 and KCNQ1 genes
5’-F]ankîng Region
Spi CpG GAGA
(3 kb) CCAAT
HERGJa 12 2 1 1
HERG1b 6 3 1 0
KCNQJa 19 2 0 0
KCNQJb 7 0 7 5
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CHAPTER 2. Transcriptional Activation by Stimulating
Protein 1 and Post-Transcriptional Repression by Muscle
Specific MicroRNAs of I-Encodïng Genes and Potential
Implications in Regional Heterogeneity of Their Expressions
In this chapter, we verified the role of Spi in the transactivation of KCNQ]
and KCNE1 genes by several methods. We also expenmentally established and
verified the repression effect of miR-1 and miR-133 on KCNQ1 and KCNE1.
Moreover, the expression distribution ofKCNQ1, KCNE1, Spi and miR-1/miR-133
were examined in different regions of the heart.
This work has been published in the Journal of Celtutar Physiotogy (2007)
Aug;2 12(2):358-67.
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2.1 Abstract
In cardiac ceils, KCNQ1 assembles with KCNE1 and forms a channel complex
constituting the slow delayed rectifier current Expression ofKCNQ1 and KCNE1
are regionally heterogeneous and changes with pathological states of the heart. The
aims of this study were to decipher the molecular mechanisms for transcriptional and
post-transcriptional regulation expression of KCNQJ and KCNEJ genes and to shed
light on the molecular mechanisms for their spatial heterogeneity of distribution. We
cloned the 5’-flanldng region and identified the transcription start sites ofifie KCNQ]
gene. We characterized the core promoters ofKCNQJ and KCNEJ and revealed the
simulating protein (Spi) as a common transactivator of KCNQJ and KCNE] by
interacting with the Spi cis-acting elements in the core promoter regions of these
genes. We also characterized the 3’ untranslated regions (3 ‘UTRs) of ffie genes and
experimentally established KCNQ1 and KCNEJ as targets for repression by the
muscle-specific microRNAs miR-133 and miR-1, respectively. We demonstrated
spatial heterogeneity of KCNQ1 and KCNE1 distributions at three axes
(interventricular, transmural and apical-basal) and disparity between mRNA and
protein expressions of these genes. We also found characteristic regional differences
of expressions of Spi and miR4/miR-133 in the heart. Our study unraveled a nove!
aspect of the cellular function of miRNAs and suggests that the I-encoding genes
KCNQJ and KCNEJ expressions are dynamically balanced by transcription factor
regulation and miRNA repression. The heterogeneities of Spi and miR-1/miR-133
offer an explanation for the well-recognized regional differences and disparity
between mRNA and protein expressions ofKCNQi and KCNEi.
2.2 Introduction
The voltage-gated KCNQ1 (KvLQT1, Kv7.1) K channels are expressed in a
variety of tissues throughout the body and regulate key physiological functions. In
cardiac myocytes, the KCNQ1 subunit assembles with the KCNE1 -subunit (minK)
and forms a channel complex constituting the slow delayed rectifier current I
(Barhanin et al., 1996; Sanguinefti et al., 1996). Mutations in KCNQJ or KCNEJ can
resuit in dysfunction of I and abnormality of cardiac repolanzation, which is
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responsible for a majority of inherited long QT syndrome. While the exact role ofIic
in cardiac repolarization is stiil incompletely understood, it is clear that it can
importantly affect cardiac action potential duration (APD) and arrhythmogenesis
through two mechanisms. First, I acts as a powerful repolarization reserve or safety
factor to restrict excessive cardiac APD and QT prolongation caused by other factors.
Removal of this safety factor by Iic blockade facilitates LQTS (Roden and Yang,
2005; Jost et al., 2005). Second, distribution of I in the heart follows important
spatial pattems in at least four different axes: (1) transmural heterogeneity with
epicardium (Epi) endocardium (Endo)> midmyocardium (Mid) (Liu et al., 1995;
Gintant, 1995; Szabo et al., 2005), (2) interventricular gradient with right ventricle
(RV) > lefi ventricle (LV) (Volders et al., 1999; Ramakers et al., 2003), transseptal
gradient with RV septum > LV septum (Ramakers et al., 2005), and apex-base
difference with apical area> basal area (Szentadrassy et al., 2005). These intrinsic
spatial paffems of distribution are important in maintaining the sequential excitations
(depolarization and repolarization) of cardiac muscles, and disruption of the pattems
andlor exaggeration of the regional heterogeneity can create substrates for
arrhythmogenesis. Many pathological conditions can change the fimction and relative
distribution ofI by altering expression ofits encoding genes (Ramakers et al., 2003;
Tsuji et al., 2006; Volders et al., 1999; Tsuji et al., 2002; Akar and Tomaselli, 2005).
Decreases in Iy density have been observed consistently in failing hearts of both
animal models and patients. KCNQ1 and KCNE1 mRNA and protein levels were
downregulated in both bradypaced and tachypaced rabbits. In chronic AV block, Iy
is reduced likely due to transcriptional downregulation of KCNQ1 and KCNE1.
Evidently, expression regulation of KCNQ1 and KCNE1 plays a critical role in
defining the physiological function ofI.
Expression of a gene is fine-tuned by its promoter sequence containing
varying cis-acting elements in the 5’-flanldng region for transcription factors to work.
In order to understand such processes, it is necessary to identify and characterize the
promoter region of a gene. In addition to transcriptional regulation, expression of a
gene is further fine-tuned by post-transcriptional regulation. Recent discovery of
microRNA-1 (miRNAs) has revolutionized our i.mderstanding ofthe mechanisms that
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regulate gene expression. MiRNAs are endogenous 22-nt non-coding RNAs that
anneal to inexactly complementary sequences in the 3 ‘UTRs of target mRNAs of
protein-coding genes to specify transiational repression or/and mRNA cleavage
(Ambros, 2004; Meister and Tuscifi, 2004; Alvarez-Garcia and Miska, 2005). Among
>300 miRNAs identified thus far, miR-1 and miR-133 are known to specifically
express in adult cardiac and skeletal muscle tissues. A recent study proposed a model
in which miR-1 and miR-133 regulate myogenesis by controlling distinct aspects of
the differentiation process; miR-1 promotes myogemc differentiation miR-133
enhances myoblast proliferation (Chen et al., 2006). Mii?-] and miR-133 are
expressed in a chamber-specific manner during cardiogenesis and are activated
during the period of differentiation (Chen et al., 2006; Zhao et al., 2005). Increasing
expression of miR-] and miR-133 has been found in neonatal hearts, and substantially
higher levels are maintained in adult cardiac tissues (Chen et al., 2006). Whether
these miRNAs are involved in regulation of ion channel expression remained
unknown.
Tins study was designed to decipher the transcriptional and post
transcriptional regulations ofI-encoding genes KCNQ1 and KCNE1, and to shed
light on the molecular mechanisms for the spatial heterogeneity of the channels. Ta
this end, we performed detailed analysis of the core promoter regions and the 3 ‘UTRs
of the genes for their putative binding elements for transcription factors and miRNAs.
We then experimentally tested the roles of the key elements in mediating the
transcriptional activation ami post-transcriptional repression of KCNQ1 and KCNE1.
FinaÏly, we also compared the spatial distribution pattems of KCNQ1/KCNE1 with
those of Spi and miR-1/miR-133 at both mRNA and protein levels, in a hope to find a
link between them.
2.3 Materïals and Methods
2.3.1 Rapid amplification of cDNA ends (5’RACE)
The transcription start sites (TSSs) of KCNQ] were detennined with
Ambion’s RNA—Ready cDNA Human Heart RNA ligase-mediated 5’RACE kit, as( previously described (Pang et al., 2003). Human RNA sample was purchased from
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Clontech. The gene specific primers were designed based on the human KCNQ1
cDNA (GenBank accession NM 0002f 2).
2.3.2 Construction of promoter-luciferase fusion plasmids
A series of fragments of varying lengifi were amplified using human genomic
DNA the Homo sapiens bacterial artificial chromosome (BAC) clone RP5-915F1
(accession No. AC124057) as a template and PCR Advantage and Advantage-GC
genomic polymerase mixes (Clontech K-1905-Y). PCR products were subcloned into
luciferase-containing PGL3-Basic (Promega) vector. The integrity and orientation of
ail constructs were confirmed by restriction endonuclease analysis and DNA
sequencing.
2.3.3 Synthesis of miRNAs and anti-miRNA antisense inhibitors
MiR-1 and miR-133 and their respective mutant constructs were synthesized
by Integrated DNA Technologies, Inc. (DT). The sequences of the anti-miR-1 and
anti-miR-133 antisense inhibitor oligonucleotides (AMO-1 and AMO-133,
respectively) used in our studies are the exact antisense copies of their respective
mature miRNA sequences and five nucleotides at both ends were locked (the ribose
ring is constrained by a methylene bridge between the 2’-O- and the 4’-C atoms).
2.3.4 Mutagenesis
Deletion mutations and base-substitution mutations were created by direct
oligomers synthesis or by PCR-based methods (Pang et al., 2003). Mutations were
made to the 5’-flanking regions ofKCNQJ and KCNEJ, and also to miR-1 and miR-
133.
2.3.5 Construction of chimeric miRNA-target site—luciferase reporter vectors
To construct reporter vectors bearing miRNA-target sites, we synthesized (by
Invitrogen) fragments containing the exact target sites for miR-1 and miR-133 or the
mutated target sites, the 3’UTRs ofKCNQ1 and KCNEJ without or with mutations by
PCR amplification. The sense and antisense strands of the oligonucleotides were
annealed by adding 2 ig of each oligonucleotides to 46 d of annealing solution (100
mmoIfL K-acetate, 30 mmollL HEPES-KOH, pH 7.4 and 2 mmolJL Mg-acetate) and
incubated at 90°C for 5 min and then at 37°C for 1 h. The annealed oligonucleotides
C were inserted into the multiple cloning sites downstream the luciferase gene (Hindiil
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and Spel sites) in the pMW-REPORT luciferase miRNA expression reporter vctor
(Ambion, Inc.).
2.3.6 Ccli culture
The ceil unes used in this study were ail purchased from American Type
Culture Collection (ATCC, Manassas, VA). H9c2 (rat ventricular cell une) and
HEK293 (human embryonic kidney ceil une) were maintain in Duibecco’s Modified
Eagle Medium (DMEM). The cultures were ail supplemented with 10% fetal bovine
serum and 100 ig/mi peniciilinlstreptomycin.
2.3.7 Transfection and luciferase assay
For promoter activity assays, 1 ig PGL3—target DNA (firefly luciferase
vector) and 0.1 ig PRL-TK (TK-driven Renilla iuciferase expression vector) were
co-transfected with lipofectamine 2000 (Invitrogen), according to the manufacturer’s
instructions.21 Following transfection (48 h), luciferase activities were measured with
a dual luciferase reporter assay kit (Promega) on a luminometer (Lumat LB9507).
The plasmid vector carrying stimulating protein 1 (Spi; CMVp-Spl) was a generous
gifi from Dr. Robert Tjian (University of Califomia, Berkeley, CA) (Kadonaga et al.,
1988; Pugh and Tjian, 1990). CMVp-Spl or Spl-free CMVp vector was co
transfected with PGL3—target DNA and PRL-TK into H9c2 celis for studying
promoter activities or they were transfected into HEK293 cells for studying native
KCNQJ expression. For miRNA experiments, ceils (1 X 1 05/well) were transfected
with 1 .ig miR-], miR-133 or other constructs (mutant miRNAs, AMO-1 or AMO
133), alone or together as to be specified, with lipofectamine 2000. For ail
experiments, transfection took place 24 h after starvation of ceils in serum-free
medium.
Drosophila Schneider cetis ($L2)
SL2 celis were cultured at 25°C in Schneider’s Drosophita medium (Gibco).
Transfection was performed using Lipofectamine 2000. The DNA transfection
mixture contained 250 ng reporter plasmid, varying amounts of pPac-Spl plasmid,
and empty pPac0 vector (kind gifis from Dr. Robert Tjian, University of Califomia)
as control (Kadonaga et al., 1988; Pugh and Tjian, 1990). Celis were haiwested 48 h
afier transfection for reporter analysis.
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C 2.3.8 Rea]-time RT-PCR
for quantification of KCNQJ, KCNE1 and Spi transcripts, conventional real
time RT-PCR was carried out with total RNA samples extracted from HEK293 celis
or human hearts 48 h afier transfection, and treated with DNase I, as previously
described (Pang et al., 2003; Zhang et al., 2006). The tissues were dissected from the
Epi of basal area for comparison between LV and RV, from basal area of LV for
comparison between Epi and Mid, and from Epi of LV for comparison between apex
and basal. TaqMan quantitative assay of transcripts was perfonned with real-time
two-step reverse transcription PCR (GeneAmp 5700, PE Biosystems), involvmg an
initial reverse transcription with random pnmers and subsequent PCR amplification
of the targets. Expression level of GAPDH was used as an intemal control.
The mirVanaTM qRT-PCR miRNA Detection Kit (Ambion) is a quantitative
reverse transcnption-PCR (qRT-PCR) kit enabling sensitive, rapid quantification of
miRNA expression from total RNA samples, and was used in conjunction with real
time PCR with SYBR Green I for quantification of the total miR-133 (miR-133a +
miR-133b) transcnpts in our study, following the manufacturer’s instructions. The
total RNA samples were isolated with Arnbion’s mirVana miRNA Isolation Kit.
Reactions contained mirVana qRT-PCR Primer sets specific for miR-i and miR-133,
or 5$ rRNA as a positive internai control. QRT-PCR was perfonned on a GeneAmp
5700 thermocycler for 40 cycles. We first determined the appropriate cycle threshold
(Ct) using the automatic baseline detennination feature. We then performed
dissociation analysis (meit-curve) on the reactions to identify the characteristic peak
associated with primer-dimers in order to separate from the single prominent peak
representing the successful PCR amplification of miR-133. Fold variations in
expression of miR-133 between RNA samples were calculated after normalization to
5s rRNA. A total number of six human heart preparations were used in this study and
they were ail from patients without heart disease. Human tissues were obtained from
the Second Affihiated Hospital of Harbin Medical University under the procedures
approved by the Ethnic Committee for Use ofHuman $amples ofthe Harbin Medical
University and from the Réseau de tissus pour études biologiques (RETEB) tissue
C bank under the procedures approved by the Human Research Ethics Committee of the
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2.3.9 Western blot
The protein samples were extracted from human heart preparations as
described above for RNA isolation and from HEK293 ceils for immunoblotting
analysis of the KCNQ1, KCNE1 and Spi proteins, with the procedures essentially the
saine as described in detail elsewhere (Zhang et al., 2006; Wang et al., 2001). For
KCNQ1 and KCNE1, membrane protein samples were extracted, and for Spi,
cytosolic protein samples were used. The protein content was determined with Bio-
Rad Protein Assay Kit (Bio-Rad, Mississauga, ON, Canada) using bovine serum
albumin as the standard. Protein sample (--30 ig) was fractionated by SDS-PAGE
(7.5%-10% polyacrylarnide gels) and transferred to PVDF membrane (Millipore,
Bedford, MA). The sample was incubated overnight at 4°C with the primary
antibodies in 1 :50—1 :200. Affinity purified goat polyclonal anti-KCNQ1 antibody,
anti-KCNE1 antibody and rabbit polyclonal anti-Spi antibody were ail purchased
from Santa Cruz and used as the primary antibodies. Jnhibitory peptide for each
antibody (Santa Cruz) was used to test the antibody specificity. Next day, the
membrane was washed in TTBS three times (10 minleach) and incubated for 2 h with
the HRP-conjugated donkey anti-goat IgG (H+L) (1:600, Santa Cruz) in the blocldng
buffer. Bound antibodies were detected using the chemiluminescent substrate
(Western Blot Chemiluminescence Reagent Plus, NEN Life Science Products, Boston,
USA). GAPDH was used as an internal control for equal input of protein samples,
using anti-GAPDH antibody from RDI (Flanders, NJ). Western blot bànds were
quantified using QuantityOne software by measuring the band intensity (Area X OD)
for each group and normalizing to GAPDH. The final resuits are expressed as fold
changes by normalizing the data to the control values.
2.3.10 Drug treatment
In experiments involving mithramycin (Sigma Chemicals), the drng was
applied to the culture medium 12 h after transfection of PGL3—target DNA was
performed, in serum- and antibiotics-free medium to starve and synchronize ceils.
The celis were further incubated for 24 h before harvested for measuring luciferase
activities in ceil unes or for extracting total RNA and protein samples.
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2.3.11 Data analysis
Group data are expressed as mean ± $.E. Statistical comparisons (performed
using ANOVA followed by Dunneft’s method) were carned out using Microsoft
Excel. A two-tailed p<O.05 was taken to indicate a statistically significant difference.
Cis-elements for transcription factor binding sites were analyzed with Matlnspector
V2.2.
2.4 Resuits
2.4.1 Transcrïptfon start sites ofKCNQJ
5’RACE techniques were used to obtain the 5’ends of KCNQJ transcripts.
The experiment using RNA samples from human heart yielded two discrete
fragments. Sequence analysis suggests that the two fragments represent separate
transcription start sites: TSS1 (designated +1) and T$$2 (position +12) which are
located 12-nt apart at $0 bp and 68 bp (GenBank accession No. EF010934),
respectively, upstream from the translation start codon (ATG) of KCNQJ (GenBanic
accession No. MN_000218) (Fig. 1). The transcription start sites of KCNE] have
been previously reported (Lundquist et al., 2006).
Promoter regions ofKCNQJ and KCNEJ
Computer analysis using the Matlnspector program of 3000-bp 5’-flanking
region of KCNQ1 revealed that it contains one TATA box located 1.4 kb upstream of
TSS1, which is unlikely to be the transcription initiation element because it is too
distal to the TSSs. The 5’-flanking region ofKCNQJ also lacks other known common
promoter elements that are required for transcription initiation complex, including the
initiator element, the downstream promoter element (DPE), or the TFIffi recognition
element (BRE). Less common promoter elements such as the downstream core
element (DCE) and the multiple start site element downstream (MED-1) are also
missing. Three GATA1 consensus sites located distal to TSS1 (1.4 kb, 1.6 kb and 2.0
kb upstream) were identified, but the heart-specific GATA4 as the potent
transactivator in cardiac ceils is absent in the KCNQ] 5’-flanking region. 0f
particular note is the high GC content of the proximal promoter region of KCNQ]
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C containing multiple Spi consensus sequences located to -61, -114, -134, -190, -259, -
277, -295, -347, -407, and -460 (fig. 1).
The functional role of the 5 ‘-flanldng region in the regulation of transcription
of the KCNQJ gene was assessed by its ability to drive expression of the luciferase
reporter gene. Varying lengths of putative promoter fragment-luciferase constructs
were generated and tested for their abiiity to drive expression of the reporter gene in a
rat ventricular celi une (H9c2), a human lung cancer celi une (A549), and a human
embryonic kidney cell line (HEK293), to map the promoter activity in the KCNQJ 5’-
flanking region. H9c2 and HEK293 were used for most parts of our study because the
former is a cardiac ceil une (Shi et al., 2002) that express significant miR-1/miR-133
but minimal endogenous KCNQ1 and KCNE1 and the latter is a human ceil une that
expresses endogenous KCNQ1 and KCNE1 lacking of miR-]/miR-133 (Zheng et al.,
2006; Vallon et al., 2001). KCNQ] promoter constructs had approximateiy 10—15
times the activity of the promoterless vector (pGL3 basic) and 50% of the promoter
activity of the pGL3 construct that contains both the SV4O promoter and enhancer
(pGL3 control, data not shown). The overail transcription activities of different
KCNQ1 promoter constructs were similar in ail three celi unes and consistently, the -
3 29/+60 fragment elicited the maximum promoter activities (Fig. 2). The core
promoter of the KC’NQl gene was thus defined to -3291+60.
Two different isoforms of KCNEJ were identified, designated KCNE]a and
KCNE]b, ofwhich KCNEJa is more prominentiy expressed in the heart (Lundquist et
al., 2006). The protein-encoding regions and the 3’ untranslated regions (3’UTRs) of
the two isoforms are identical. The core promoter region of KCNEJa was mapped to -
244 bp upstream ofthe TSS and it shares some similarities with that of KCNO1, with
a cluster of five putative Spi cis-elements (-50, -97, -133, -145, and -198), without
other known transactivator elements. The core promoter of KCNE1b (-921/+70) also
contains several putative Spi binding sites. Thus, only KCNEYa was used for
luciferase activity measurements and KCNE1 (including both KCNE1a and KCNEIb)
was used for ah other experiments.
2.4.2 Spi as a transcription activator ofKCNQ1 and KCNEIa
C
8$
C Apparently, a common feature of the KCNQ] and KCNEJ core promoters
the presence of multiple Spi consensus binding sites. Spi is a wideiy distributed
member of a multigene family of zinc-finger transcription factors that binds DNA in
mammalian celis primarily via interaction with GC-box elements. The binding of Spi
to GC-boxes is often critical to achieving significant levels of transcription from
TATA-less promoters and is intimately involved in the determination of TSS
(Kadonaga et al., 198$; Pugh and Tjian, 1990; Black et al., 2001; Courey and Tjian,
1998).
To investigate the role of Spi in the transcription of KCNQJ and KCNE1a
genes, we first assessed the effects of Spi inhibitor mithramycin (Pugh and Tjian,
1990; Courey and Tjian, 1998) on the luciferase activities driven by the core
promoters of these genes in H9c2 ceils and endogenous expressions of these genes at
mRNA and protein levels in HEK293 ceils. As depicted in Figure 3A and 3B,
mithramycin produced considerable reduction of the promoter activities and of
expression levels of native KCNQJ and KCNE1a transcripts and proteins.
We then evaluated the effects of Spi overexpression on KCNQJ and KCNEJa
expression by co-transfection of CMVp-Spi vectors with KCNQ1 or KCNEJa
canying PGL-3 vectors in H9c2 cells to study the promoter activities and by
transfection of CMVp-Sp 1 into HEK293 celis to study endogenous mRNA levels of
KCNQJ and KCNEJ genes. Spi overexpression strikingly enhanced the promoter
activities and native transcript levels, as compared with transfection of Spi -nuli
CMVp vectors (Fig. 3C).
We reasoned if Spi is indeed important for the promoter activities of KCNQ]
and KCNE]a, then in a Spi-nuil environment, such as the SL2 ceils (Bond et al.,
2004), the core promoter fragments should lose their ability to elicit luciferase
activities unless exogenous Spi is supplied. This notion was verified by our
experiments using SL2 cells. The luciferase reporter activity was undetectable with
any one of the core promoter fragments in absence of exogenous Spi cDNA, whereas
in the SL2 celis co-transfected with Spi cDNA, it was readily detectable (Fig. 3D).
Furthermore, a series of truncation mutations and site-directed mutations were
made to determine the relative importance of the Spi cis-elements in the core
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promoter region of KCNQ]. The truncation mutations were designed as such ,that
each fragment contains a certain numbers of Spi cis-elements. For instance, the -
871+60 fragment contains only the first Spi site (-61), the -189/+60 fragment contains
a group of Spi sites (-1 141-134/-190) in addition to the first Spi site. As shown in
Figure 2, the fragment containing only the first Spi cis-elements demonstrated as
much as j—30% ofthe maximum reporter activities conferred by -3291+60 fragment in
H9c2 cardiac celis, but nearly nuli HEK293 kidney ceils, indicating the first Spi cis
element accounting for initiation of promoter activity and being required for
maintaining the minimal transcriptional activity ofKCNQJ in cardiomyocytes. When
the fragment was lengthened to include the subsequent three Spi cis-elements (-114/-
134/-190) to form the - 189/+60 fragment, the reporter activity robustly increased to
-85% ofthe maximum activity conferred by -3291+60 fragment that contains another
cluster of Spi sites ffirther upstream of the TSS. The resuit indicates that the Spi cis
elements located at -60, -114, -134 and -190 are the most critical sites defining the
core promoter region ofKCNQJ.
2.4.3 MiR-133 as a post-transcriptional repressor ofKCNQ1
Neither KCNQ] nor KCNEJ genes are listed as candidate targets for miR-]
and miR-133 according to the prediction by TargetScan hosted by Wellcorne Trust
Sanger Institute (Griffiths-Jones, 2004). However, by detailed analysis of the 3’UTR
of KCNQJ, we identified four putative binding sites for miR-133 based solely on
complementarity, each of them containing six nucleotides exactly matching the 2-7
nucleotides from the 5’-end of miR-133 (Fig. 4A and 4B). No sites with tuore than
five complementary nucleotides to miR-1 were found in the 3’UTR ofKCNQ].
Perturbation of miRNA expression, including overexpression and silencing, is
a powerful approach to study miRNA function (Cheng et al., 2005; Chan et al., 2005;
Krutzfeldt et al., 2005). Transient overexpression ofmiRNAs in cell-based assays can
be achieved by transfection of double-stranded RNA molecules that mimic the Dicer
cleavage product. Moreover, the anti-miRNA antisense inhibitor oligonucleotides
(AMOs) specifically and stoichiometrically bind, and efficiently and irreversibly
silence, their target miRNAs, by competitive binding to miRNAs, and by degrading
them as well with unknown mechanisms. To verify that KCNQJ is indeed the cognate
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C targets of miR-133 for post-transcriptional repression, we took the following
approaches. We first inserted the 3 ‘UTR of KCNQ1 into the 3 ‘UTR of a luciferase
reporter plasmid containing a constitutively active promoter in order to determine the
effects of miR-133 on reporter expression. Co-transfection of the chimeric luciferase
KCNOJ 3 ‘UTR vector with miR-133 (Fig. 4C) into HEK293 ceils that express
minimal miR-l/miR-133 consistently demonstrated smaller luciferase activities
relative to transfection of the chimeric plasmid alone or co-transfection with the
mutant miR-133 failed to produce any effects. Co-application of miR-133 with AMO
133 eliminated the silencing effect on luciferase reporter activities. A mutated miR-
133 failed to elicit any effects.
As a second step, we used miR-1 and miR-133 standards in winch the
complementary sequences of miR-1 and miR-133 were cloned downstream of
luciferase gene in the pMW-REPORT plasmid (Chen et al., 2006; Cheng et al., 2005).
With these constructs, we were able to confinu the uptake and activities of
transfected miRNAs. Our experiments demonstrated that co-transfection of miR-133
into HEK293 ceils nearly abolished the luciferase activities seen with transfection of
the plasmid containing miR-133 standards alone. The luciferase expression was
unaffected if miR-1 was co-transfected with miR-133 standards (Fig. 4D).
b see if KCNQJ repression by miR-133 reported by luciferase assays has
functional implications, we determined the effects of miR-133 on endogenous
expression of KCNQ1 at protein levels by Western blot with HEK293 membrane
protein samples. Our data showed that transfection of miR-133 at 10 nM remarkably
reduced KCNQ1 protein level, and as a negative control the mutant miR-133 did flot
cause any appreciable changes (Fig. 4EC). Co-application of miR-133 with its
antisense (AMO-133) nearly abolished the effects, verifying the specificity of the
miR-133 action. Transfection of miR-1 (100 nM) failed to affect KCNQ1 protein
level, validating base-pairing as a major criterion for miRNA targeting. Moreover,
transfection of AMO-133 alone significantly increased KCNQ1 protein level,
presumably by removing the inhibitory effect of endogenous miR-133. By
comparison, miR-133 produced marginal reduction ofKCNQ1 mRNA level (Fig. 4F),
indicating that miR-133 does flot affect KCNQ 1 mRNA stability.
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C 2.4.4 MiR-1 as a post-transcriptional repressor ofKCNEJ
By comparison, the 3’UTR ofKCNEJ (KCNE1a and KCNE]b have the same
3 ‘UTR) contains three putative miR-1 binding sites with each carrying at least seven
consecutive complementary nucleotides to the 5’-end of miR-1, but it does flot
contain miR-133 target sites (Fig. 5A). Similar approaches to those described for
KCNQJ were applied to KCNEJ. Our experiments demonstrated that KCNE1 is
cntically regulated by miR-1, but flot by miR-133; miR-1 (10 nM) produced some
79% abrogation of the luciferase activity reported by the vectors carrying the 3 ‘UTR
of KCNEJ and 70% reduction of KCNE1 protein level (Fig. 5C and 5E). Notably,
transfection of AMO-1 alone significantly increased KCNE1 protein level (Fig. 5E).
The KCNE1 mRNA was unaffected by miR-1 (Fig. 5F).
We then verifled the transfection and effect of miR-1 using the miR-1 standard
as described above. Co-transfection of miR-1 into HEK293 celis nearly abolished the
luciferase activities seen with transfection of the plasmid containing the miR-1
standard alone. The luciferase expression was unaffected if miR-133 was co
transfected with the miR-1 standard (Fig. 5D).
The mechanism of actions of AMOs was verified by real-time RT-PCR
quantification of mil?-] and miR-133 in H9c2 celis that express endogenous miR
]/miR-]33, since AMOs have been shown to degrade their target miRNAs through
some unknown mechanisms. As shown in Figure 5G, AMO-1 speciflcally reduced
the endogenous miR-1 level when applied alone or the total miR-1 levels when co
transfected with exogenous mil?-], without notable effects on miR-133 levels. Vice
versa, AMO-133 specifically decreased miR-133 level without altering mil?-].
2.4.5 Spi and miR-1/rniR-133 and their roles in regional heterogeneity ofKCNQJ
and KCNEJ expressions
As already described in Introduction, Iy along with its underlying channel
proteins KCNQ1 and KCNE1 demonstrates important spatial heterogeneity of
distribution. This regional inhomogeneity exists along at least three axes including
transmural difference (Epi>Mid), interventricular gradient (RV>LV) and apex-base
asymmetry (Apex>Base). In order to investigate if Spi and miR-1/miR-133 contribute
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to the spatial heterogeneity ofI in human heart, we first quantified the I1-encoding
genes KCNQ1 and KCNE1 at both protein and mRNA levels. Western blot analysis
revealed that KCNQ1 protein level was predominant in RV vs. LV (1.7:1), in Epi vs.
Mid (1.6:1) and in Apex vs. Base (2.2:1). Similarly, the protein level ofKCNE1 was
also found RV>LV (2:1) and Apex>Base (1.5:1); however, it was more pronounced
in Mid than in Epi (1.4:1), opposite to the distribution ofKCNQ1 channels. (fig. 6,
upper). Real-time RT-PCR quantification ofKCNQJ and KCNE] transcripts showed
that the mRNA levels of both KCNQJ and KCNE] were higher in RV than in LV
(Fig. 6, lower). By comparison, we found no such a regional difference of KCNQÏ
and KCNE1 in mRNA levels between Epi and Mid and between Apex and Base.
We subsequently quantified the expression of Spi using the same mRNA and
protein samples as for KCNQ1/KCNE1. The anti-Spi Western blot showed a Spi
protein doublet at 110 kDa and 95 kDa positions (Bond et al., 2004). Notably, both
the major (95 kDa) and the minor (110 kD) bands were signiflcantly higher in their
densities with RV than with LV samples (2.2:1). The abundance of Spi transcripts
was in good agreement with the interventricular gradients of KCNQJ and KCNE]
transcripts, being RV>LV with a ratio of approximately 2.4:1 (fig. 7A). However, no
significant differences of Spi transcripts and proteins were observed in the
transmural and apical-basal axes (Fig. 7A).
Strikingly, the regional distribution profiles of miR-1 and miR-133 were converse
to those of Spi transcripts. Neither miR-1 nor miR-133 showed any appreciable
interventricular differences. However, the transmural and apical-basal gradients were
consistently seen. For miR-1, the levels were Epi>Mid (1 .4:1) and Base>Apex (1.5:1)
(Fig. 7B), and for miR-133, the levels were Mid>Epi (2.8:1) and Base>Apex (2.5:1)
(Fig. 7C).
2.5 Discussion
The aims of this study were to explore the molecular mechanisms for
transcriptional and post-transcriptional regulation of expression of KCNQJ and
KCNE1 genes and to shed light on the molecular mechanisms of spatially
C heterogeneous expressions of these genes. We identifled the simulating protein (Spi)
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as an important transactivator ofKCNQ1 and KCNE1 by interacting with the Spi, cis
acting elements in the core promoter regions of these genes. We also experimentally
established KCNQ1 and KCNE1 as targets for repression by the muscle-specific
miRNAs miR-133 and miR-1, respectively, which unraveled a novel aspect of the
cellular function of miRNAs. We demonstrated, for the first time, that expressions of
Spi and miR-1/miR-133 in the heart are spatially heterogeneous, and these
heterogeneities may contribute to the well-recognized regional differences of
distribution 0fKCNQ1 and KCNE1.
Having generated a tremendous amount of excitement about miRNAs in many
areas of biology, research over the past five years has put miRNAs at centre stage.
Indeed, miRNA-mediated gene regulation is now considered a fundamental layer of
genetic programs that operates at the post-transcriptional level. However, in spite of
our ability to identify miRNAs, regulatory targets have flot been established or even
confidently predicted for any of the vertebrate miRNAs, which has hampered
progress toward elucidating the functions of miRNAs. Our current understanding of
the functions of miRNAs primarily relies on their tissue-specific or developmental
stage-specific expression pattems as well as their evolutionary conservation, and is
thus largely limited to biogenesis and oncogenesis. Target finding and function
discovery are two major challenges to researchers in miRNA research. Based on
computational predictions, neither KCNQ 1 nor KCNF 1 were considered targets for
miR-1/miR-133, despite that they both have substantial complementarity to the
miRNAs, likely due to unfavorable free energy status. However, by detaild analysis
of the 3’UTR of KCNO1, we identified four putative binding sites for miR-133 (Fig.
4A). Similarly, the 3’UTR of KCNEJ was found containing three putative miR-1
binding sites (Fig. 5A). These multiple sites may cooperate with one another to
confer significant effects of the miRNAs. Our experimental data convincingly
demonstrated that the expression levels of KCNQ 1 and KCNE 1 are importantly
regulated by miR-133 and miR-1, respectively. Consistent with the principle of action
of miRNAs, miR-133 and miR-1 decreased KCNQ1 and KCNE1 protein level
without significantly affecting their mRNA levels. It is not clear at this time what
pathophysiological implications of this post-transcriptional repression are. One might
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speculate that the miRNAs can act to limit excessive expression of KCNQ 1 and
KCNE1 genes, if any. As to be discussed below, our study also revealed for the first
time that distribution of the miRNAs in aduit human hearts is heterogeneous and this
heterogeneity may contribute to regional asymmetry of many proteins.
Since the beginning of the last decade, when Day, McComb, and Campbell
(Day et al., 1990) introduced the concept of QT dispersion as a potential marker of
arrhytbmogenicity nsk and hence of cardiovascular morbi—mortality, vanous
electrocardiographic ventricular repolarization parameters have been tested as
prognostic factors in several conditions such as coronary heart disease, heart failure,
cardiomyopathies, as well as in population-based studies. QT dispersion mainly
reftects regional dispersion of ventricular repolarization or APD. Under normal
physiological conditions, these regional differences are genetically programmed with
a certain pattem with APD gradient from long to short following the sequence of
activation of myocardial mass during an excitation, which constitutes an intrinsic
protection mechanism against arrhythmias which could be induced due to radial and
retrograde excitation propagation. Under pathological situations, the spatial
heterogeneity is abnormally increased and the intrinsic paffem of spatial
heterogeneity may also be broken. These changes render the heart a loss of the
intrinsic antiarrhythmic mechanism and a vulnerability to arrhythmogenesis. For
example, enlarged interventricular differences have been shown to cause acquired
LQT$ (Verduyn et al., 1997a and 1997b). The spatial heterogeneity of cardiac
repolarization is largely due to diversity and varying densities of repolarizing K
currents. The well-recognized regional heterogeneity of Iy is one of the important
factors determining the spatial dispersion of electrical activities (Liu et al., 1995). In
this study, we qualitatively reproduced the resuits reported in previous published
studies: (1) KCNQ1 and KCNE1 distribute with significant interventricular gradients
(RV>LV) at both mRNA and protein levels (Ramakers et al., 2003), (2) The protein
levels of both KCNQ1 and KCNE1 are higher in apical than in basal area
(Szentadrassy et al., 2005), despite that their mRNA levels are flot significantly
different, and (3) KCNQ1 protein level is greater in Epi than in Mid (Szabo et al.,
2005), whereas that of KCNE1 is the opposite, and there is not transmural difference
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in rnRNA levels of KCNQ1 and KCNE1 (Pereon et al., 2000). Clearly, in additipn to
the regional difference of KCNQ1 and KCNE1 expressions, there is also a consistent
discrepancy between the protein and mRNA expressions of these genes. Intriguingly,
the distribution pattems of Spi and miR-1/miR-133 seem to provide a reasonable
explanation for the observations and this can be sorted out as following. First, the
interventricular difference of Spi, which drives KCNQ1 and KCNE1 expressions,
corresponds exactly to the interventricular differences of KCNQi and KCNE1, at
both mRNA and protein levels. By comparison, miR-1 and miR-133 do not show any
chamber-dependent difference. These suggest that the higher abundance of Spi in RV
likely contributes to the higher abundance of KCNQ1 and KCNEi in the sarne
chamber. Second, there is no difference of Spi expression either across the LV wall
or along the apical-basal axis, coincident with the uniformity of distributions of
KCNQi and KCNE1 transcripts in these two axes. Most strikingly, the miR-133 level
was found much greater in Base than in Apex and in Mid than in Epi. Considering the
fact that miR-133 represses KCNQ1 proteins leaving its transcripts unaltered, it is flot
difficuit to understand why KCNQ1 protein levels have the opposite pattems of
transmural and apical-basal gradients to those of miR-133 but KCNQ1 mRNA does
not have transmural and apical-basal gradients. The sarne logic can be applied to miR-
1 and KCNE1; the characteristic regional distributions of miR-1, Base>Apex and
Epi>Mid, can be one of the causal factors for the converse transmural and apical-
basal gradients ofKCNE1 protein levels. It seems reasonable to corne to a conclusion
that the combination and interplay of the characteristic spatial distributiôns of Spi
and rniR-1/miR-133 account, at least partially, for the regional heterogeneity ofI
encoding genes and the disparity between protein and mRNA expressions of these
genes. It should be mentioned, however, that our data are only supportive, but not
confirmative, to this notion. further studies using in vivo genetic engineering of Spi
and miR-1/miR-133 are absolutely needed to fully estabïish the link.
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2.8 Figures and Figure Legends
Figure 1 The 5’-flanking regions containing the core promoter sequence and
transcription start sites ofthe KCNQJ. Transcription start sites (TSSs) are
indicated by backward arrows and designated position +1. The consensus
binding sequences for Spi transciiption factor are underlined and core
sequences of the Spi cis-elements are bold. for convenience, the Spi
consensus sites are numbered in order from TS$ and the positions,
relative to TSS, at the first nucleotide of the consensus core sequence are
donated by the numbers in the brackets. The core promoter sequence
KCNEIa is presented for comparison.
Figure 2 Analysis of the KC’NQJ promoter activities in various celi unes. A
schematic representation of the 5’ deletion constructs of the KcNQJ
promoter region is shown in up-Iefi panels. Nucleotides of fusion
plasmids are numbered with respect to the TSS (+1) identified by
5 ‘RACE. Firefly luciferase expression levels were divided by co
expressed Renilla luciferase activity and expressed as relative activity
divided by the promoter-less construct (PGL3-Basic). The experiments
were performed in duplicate for each experiment and the number (n) of
experiments is indicated in the brackets.
Figure 3 Role of stimulating protein 1 (Spi) as a common driving factor for
KCNQJ and KCNEJa transcriptions. (A) and (B) Effects of Spi inhibitor
mithramycin (100 nM) on the activities of the core promoters (KCNQ]: -
3291+60 and KCNEJa: -244/+257) and endogenous mRNA levels were
evaluated in H9c2 ceils. *p<o.05 vs. PGL3-Basic (Base) or Control (Ctl);
n=5 for each group. (C) Effects of Spi overexpression (+CMVp-Spi) on
KC’NQJ and KC’NEJa promoter (-3291+60 and -2441+257, respectively)
activities and endogenous mRNA levels in HEK293 celis. +CMVp: co
transfection of Spi-nuli CMVp vector and target DNA-PGL-3 vectors.
*p<O.05 +CMVp-Spi vs. +CMVp; n=6 for each group. (D) Reporter
activities of the core promoter fragments of KCNQJ (-329,’+60) and
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KCNEJa (-244/+257) in Spl-null Drosophila Schneider ceils (SL2).
Celis were transfected with Spl-free plasmid (pPac) or with Spl-carrying
plasmid (pPac-Spl). *p<0.05 pPac-SpI vs. pPac; n=4 for each group.
The experiments were performed in duplicate for each experiment.
Figure 4 Post-transcriptional repression of KCNQ1 by the muscle-specific
microRNA miR-133. (A) The complementarity (bold font) between miR-
133 and each of the four target sites in the 3’UTR of KCNQJ. (B)
Sequences of miR-133, mutant miR-133 and anti-miR-133 antisense
inhibitor oligonucleotides (AMO-133). Bold-face leffers indicate the ‘seed
site’ critical for miRNA: :mRNA binding and interaction; lower-case letters
indicate the base substitution mutations made to the sequences; italics in
the AMO-133 indicate the locked nucleotides (the ribose ring is
constrained by a methylene bridge between the 2’-O- and the 4’-C atoms,
to confer a higher thermal stability, discriminative power and a longer
haif-life). (C) Luciferase reporter activities showing the interaction
between miR-133 and KCNQ1-3’UTR in HEK293 celis. miR-133 (10
nM), mutant miR-133 (100 nM, Mt-133), +AMO-133 (100 nM) or miR-]
(10 nM). The “+“ before the labels indicate co-transfection with miRNA.
*p<0.05 vs. Ctl; +p<O.O5 vs. miR-133 (10 nM); n=6 for each group. (D)
Luciferase reporter activities verifying the interactions of miR-133 with
its exact binding sequence (standard) in HEK293 ceils. p<O.O5 vs. Ctl;
n=8 for each group. (E) Western blot analysis of KCNQ1 prôtein level
under various conditions with protein samples isolated from HEK293
celis. AP: antigenic peptide pretreatment. *p<0.05 vs. Ctl; +p<O.O5 vs.
miR-133 (10 nM); n=5 for each group. (F) Real-time RT-PCR analysis of
KCNQ1 mRNA levels in HEK293 cells. *p<0.05 vs. Ctl; +p<O.OS vs.
miR-133 (10 nM); n4 for each group.
Figure 5 Post-transcriptional repression of KCNE1 by the muscle-specific
microRNA miR-]. (A) The complementarity (bold font) between miR-]
and each ofthe four target sites in the 3’UTR ofKCNEJ. (B) Sequences of
miR-], mutant mi]?-] and anti-miR-1 antisense inhibitor oligonucleotides
I
1V.
(J (AMO-1). Bold-face letters indicate the ‘seed site’ critical for
miRNA: :mRNA binding and interaction; lower-case letters indicate the
base substitution mutations made to the sequences; italics in ifie AMO-1
indicate the locked nucleotides. (C) Luciferase reporter activities showing
the interaction between mil?-] and KCNEJ-3’THR in HEK293 ceils.
miR-] (10 nM), mutant miR-1 (100 nM, Mt-1), AMO-1 (100 nM) or
miR-133 (10 nM). The “+“ before the labels indicate co-transfection with
miRNA. *p<0.05 vs. Ctl; +p<0.05 vs. miR-1 (10 nM); n=5 for eaeh group.
(D) Luciferase reporter activities verifying the interactions of mil?-] with
its exact binding sequence (standard) in HEK293 celis. *p<0.05 vs. Ctl;
n=8 for each group. (E) Western blot analysis of KCNE1 protein level
(35 kDa) under various conditions with protein samples isolated from
HEK293 celis. AP: antigenic peptide pretreatment. *p<0.05 vs. Ctl;
+p<O.O5 vs. miR-1 (10 nM); n=6 for each group. (F) Real-time RT-PCR
analysis of KCNE1 mRNA levels in REK293 celis. *p<O.05 vs. Ctl;
+p<0.05 vs. miR-1 (10 nM); n=4 for each group. (G) Real-time RT-PCR
analysis of miR-1 and miR-133 levels in H9c2 ceils. Transfection of
AMO-1 (10 nM) and AMO-133 (10 nM) alone for studying the
endogenous miRNAs or co-transfection with miR-l (10 nM) or miR-133
(10 nM), as indicated by +AMO-1 or +AMO-133, for verifying the
efficacy against the exogenous miRNAs. *p<0.05 vs. Ctl; n=5 for each
group.
Figure 6 Regional differences of expressions of KCNQ1 (A) and KCNE1 (B) at
protein and mRNA levels, determined by Western blot and real-time-RT
PCR, in human hearts. Protein and RNA samples were isolated from lefi
(LV) and right ventricular (RV) epicardium, epicardium (Epi) and
midmyocardium (Mid) of lefi ventricular wall, and apical (Apex or Ax)
and basal (Base or Bs) areas of lefi ventricular epicardium. *p<0.05,
Unpaired Student t-test; LV vs. RV, Epi vs. Mid, or Apex (Ax) vs. Base
(Bs). The number of samples used for data analysis is indicated in the
brackets.
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Fïgure 7 Regional differences of expressions of Spi (A) and miR-1 (B) and miR
133 (C) genes in human hearts. *p.<0.05, Unpaired Student t-test; LV vs.
RV, Epi vs. Mid, or Apex (Ax) vs. Base (Bs). The number of samples
used for data analysis is indicated in the brackets.
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Cliapter 3. MicroRNA miR-133 Represses HERG K’
Cliannel Expression
In this chapter, we experimentally established the post-transcriptional
repression of HERG1 by miR-133. We also examined the role of miR-133 in
determining the disparate expression of HERG1 on mRNA and protein levels under
diabetic condition.
This work is published in the Journal of Biotogical Chemistry 2007;
282(17): 12363-7.
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3.1 Abstract
Discovery of microRNA (miRNA) has revolutionized our understanding of
the mechanisms that regulate gene expression. However, the potential
pathophysiological roles of the muscle-specific microRNA miR-133 in aduit hearts
remained unexplored. We have previously found that the ether-a-go-go related gene
(ERG), a long QT syndrome gene encoding a key K charme! (I) in cardiac ceils, is
severely depressed in its expression at the protein level but not at the mRNA level in
diabetic subjects. The mechanisms underlying the disparate alterations of ERG
protein and mRNA, however, remained unknown. We report here a remarkable
overexpression of miR-133 in hearts from a rabbit mode! of diabetes, and in parallel
the expression of serum response factor (SRF), which is known to be a transactivator
of miR-133, was also robustly increased. Delivery of exogenous miR-133 into the
rabbit myocytes and celi lines produced post-transcriptional repression of ERG,
downregulating ERG protein level without altering its transcript level and caused
substantial depression of Igj, an effect abrogated by the miR-133 antisense inhibitor.
The mutant miR-133 failed to produce any effects. Functional inhibition or gene
silencing of SRF downregulated miR-133 expression and increased Iic density.
Repression of ERG by miR-133 likely underlies the differential changes of ERG
protein and transcript thereby depression of ‘Ki, and contributes to repolarization
siowing thereby QT prolongation and the associated arrhythmias, in diabetic hearts.
Our study provided the first evidence for the patho!ogical role of miR-133 in aduit
hearts, and thus expanded our understanding of the cellular fiinètion and
pathophysiological roles ofmiRNAs.
3.2 Introduction
Abnormal QT interva! prolongation is a prominent electncal disorder and has
been proposed a predictor of mortality in patients with diabetes mellitus (DM),
presumably because it is associated with an increased risk of sudden cardiac death
consequent to lethal ventricular arrhythmias (1-8). Our recent study revealed that the
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long QT syndrome gene, human ether-a-go-go-related gene (HERU) encoding the
channel responsible for rapid delayed rectifier K current (Icj-), is signiflcantly
downregulated in its expression in diabetic hearts and this downregulation contributes
critically to diabetic repolarization siowing and QT prolongation (9,10). Sftilcingly,
HERG expressions at transcriptional and post-transcriptional leyels diverge in
diabetic hearts, with its protein levels being reduced by some 60% while the mRNA
levels remaining essentially unaltered (10). These disparate changes indicate that
HERG expression is impaired mainly at the post-transcriptional level; however, it
remained unclear what are the determinants for the differential regulations of HERG
expression at protein and transcript levels.
MicroRNAs (miRNAs) are endogenous 22-nt non-coding RNAs that anneal
to inexactly complementary sequences in the 3’UTRs of target mRNAs of protein
coding genes to regulate gene expression. The major characteristics of miRNA
actions is to specify translational repression without affecting the levels of the
targeted mRNA (11,12). Among >300 miRNAs identified thus far, miR-1 and miR-
133 are known to specifically express in aduit cardiac and skeletal muscle tissues
(13,14). Recent studies revealed that mil?-] and miR-133 play critical roles in
regulating myogenesis. Increasing expression of miR-1 and miR-133 has been found
in neonatal hearts and substantially higher levels are maintained in aduit cardiac
tissues (14), suggesting that in addition to regulating myogenesis, they may also
possess other cellular functions in aduit cardiac celis. However, our current
understanding of the function of these miRNAs is stiil limited to developmental
regulation and their possible roles in other cellular processes have not yet been
explored.
We proposed that the muscle-specific miRNAs miR-1/miR-133 are able to
repress HERG translation while keeping its mRNA unaffected and their levels are
upregulated in diabetic hearts, winch causes the disparate changes of HERG protein
and mRNA levels. Tins study was designed to test tins hypothesis.
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3.3 Experimental Procedures
3.3.1 Preparation of Rabbit Model of Diabetes Mellitus (DM)
Male New Zealand white rabbits weighing 1 .6—2.0 Kg (Charles River Canada
mc) were used and the procedures for development of alloxan-induced DM model
were the same as previously descnbed in detail (9,10). The QT measurements and
simultaneously recorded RR intervals were used to derive heart rate corrected QT
intervals. Incidences of ventricular tachycardia (VT) and ventricular fibrillation (Vf)
were determined. Ail procedures are in accordance with the guidelines set by the
Animal Ethics Commiftee of the Montreal Heart Institute and of Harbin Medical
University.
3.3.2 Isolation of Rabbit Ventricular Myocytes and Ccli Culture
Myocytes were isolated from rabbit lefi ventncular endocardium via
enzymatic digestion of the whole heart on a Langendorff apparatus with the
procedures simiiar to previously described (9,10). The freshly isolated myocytes were
stored either in the extracellular solution for patch-clamp recordings or in 199
Medium as detailed elsewhere (9,15).
3.3.3 Whole-Cell Patch-Clamp Recording
Patch-clamp recording of I currents has been described in detail eisewhere
(9,10).
3.3.4 Synthesis of miRNAs and Anti-m1RNA Antisense Inhibitors nd Their
Mutant Constructs
Mi]?-] and miR-133 and their respective mutant constructs were synthesized
by Integrated DNA Technologies, Inc. (T) as detailed elsewhere (16) (also see
Supplementary Fig. 1). The mutant miRNAs each had eight nucleotides mismatches
at the 5’-end, which disrupts their binding to the target sites and thus tums the
miRNAs into negative controls (11-14,16).
3.3.5 Construction of Chimeric miRNA-larget Site—Luciferase Reporter
Vectors
b construct reporter vectors bearing miRNA-target sites, we synthesized (by
Invitrogen) fragments containing the exact target sites for miR-1 and miR-133 or the
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mutated target sites, HERG cDNA and inserted these fragments into the multiple
cloning sites downstream the luciferase gene (Hindiil and Spel sites) in the pM]R
REPORTTM luciferase miRNA expression reporter vector (Ambion, Inc.), as detailed
elsewhere (16).
3.3.6 SmaIl Interference RNA (siRNA) Treatment
The StealthTM siRNAs targeting SRF (sense:
5 ‘GCAGAGGCAACUGACUUCAUUUGUG3’ and antisense:
5’CACAAAUGAAGUCAGUUGCCUCUGC3’; 3096-3131) and anegative control
siRNA (sense: 5’GCAACGGGUCAUUCAUUACUAGGUG3’ and antisense:
5’CACCUAGUAAUGAAUGACCCGUUGC3’; 3096-3131) were synthesized by
Invitrogen.
3.3.7 Ccli Culture
SKBr3 (human breast cancer ccli une) and HEK293 (human embryonic
kidney ccli une) were purchased from American Type Culture Collection (ATCC,
Manassas, VA). The celis were cultured as previously described (17)
3.3.8 Transfection and Luciferase Assay
The transfection procedures for ceil unes and rabbit cardiac myocytes in
primary culture, and luciferase activity assays were the same as described in detail
elsewhere (16,17). Before transfection, celis were starved to synchronize growth by
incubating in serum- and antibiotics-free medium for 12 h.
3.3.9 Quantification of mRNA and miRNA Levels
The procedures for quantification ofHERG and serum responsive factor ($RF)
transcripts by conventional Taqman real-time RT-PCR were the same as previously
described (16).
The mirVanaTM qRT-PCR miRNA Detection Kit (Ambion), a quantitative
reverse transcnption-PCR (qRT-PCR) kit was used in conjunction with real-time
PCR with SYBR Green I for quantification of miR-1 and miR-133 (miR-133a + miR
133b) transcripts (16). The total RNA samples were isolated with Ambion’s mirVana
miRNA Isolation Kit from SKBr3 celis, HEK293 celis, rabbit hearts and human
hearts. Fold variations in expression of miR-133 between RNA samples were
calculated afler normalization to 5s rRNA. Human tissues were obtained from the
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Second Affihiated Hospital of Harbin Medical University under the procecures
approved by the Ethnic Committee for Use ofHuman Samples ofthe Harbin Medical
University and from the Réseau de tissus pour études biologiques (RETEB) tissue
bank under the procedures approved by the Human Research Ethics Committee ofthe
Montreal Heart Institute. The criteria for inclusion of the tissues in our study were the
patients that did not have primary heart problems at the time of death.
3.3.10 Western Blot
The procedures for semi-quantification of ERG and SRF protein levels were
the same as described in detail elsewhere (9,10,15-17). Membrane protein sampies
were extracted from lefi ventricular wall of rabbits and SKBr3 celis. The goat
polyclonal antibodies against ERG and SRF were both purchased from Santa Cruz
Biotechnology Inc.
3.3.11 Data Analysis
Group data are expressed as mean ± S.E. Statistical comparisons (performed
using ANOVA followed by Dunnett’s method) were carried out using Microsoft
Excel. A two-tailedp<0.05 was taken to indicate a statistically significant difference.
3.4 Results
3.4.1 Overexpression of miR-1 and miR-133 and Downregulation of ERG
Protein Level in Diabetïc Hearts
Both miR-] and miR-133 were expressed in rabbit hearts; howevet, miR-133
was approximately 10 times more abundant than that of miR-1. The levels of both
miR-] and miR-133 were found some 2.2 folds and 3 folds higher, respectively, in the
ventricular RNA samples from rabbits with DM than those from healthy control
animais. Upregulation of the muscle-specific miRNAs was also observed in the
ventricular samples from DM patients (Fig. 1).
We also reproduced the observations reported in our previous study (9,10),
i.e., the protein level of the rabbit ERG (rbERG) was significantly lower in diabetic
hearts than in healthy hearts despite that the transcript level remained unchanged. We
further demonstrated the same disparity between HERG protein and mRNA
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Ç. expression levels in the hearts from DM patients (Fig. 1). Note that the molecular
masses of ERG in rabbit (155 kDa and 135 kDa) and human (140 kDa and 120 kDa)
were somewhat different presumably due to different glycosylations in different
species; the larger band represents the mature glycosylated form and the smaller band
represents the non-glycosylated form of ERG protein (16). The size rbERG is
consistent with our previous finding (9,10) and that of HERG is identical to the
resuits reported by Jones et al (18).
3.4.2 Post-Transcriptional Repression of NERG Expression by miR-133
HERG and rbERG share 91% homology in their sequences. We identified
multiple putative target sites for miR-133 in rbERG and in KERG based on
complementarity: at least six nucleotides exactly matching the 2-10 nucleotides from
the 5’-end of miR-133 (Supplementary Fig. 1). These sites may cooperate to confer
the regulation by miR-133. Neither HERG nor rbERG contains any sites with more
than five complementary nucleotides to miR-1.
To verify that HERG and rbERG are the cognate targets of miR-133 for post
transcriptional repression, we first inserted HERG cDNA into the 3’UTR of a
luciferase reporter plasmid containing a constitutively active promoter in order to
determine the effects of miR-133 on reporter expression. Co-transfection of miR-133
and the chimeric luciferase-HERG vector into HEK293 celis consistently
demonstrated smaller luciferase activities relative to transfection of the chimeric
plasmid alone, but co-transfection of the mutant miR-133 (M-miR-133) failed to
produce any effects (Fig. 2A). HEK293 celis were used for luciferase reporter assays
because these cells do flot express endogenous ERG protein and miR-limiR-133
(Supplementary Fig. 2). Co-application of miR-133 with its antisense inhibitor
AMO-133 eliminated the silencing effect on luciferase reporter activities (16,19,20).
As an additional negative control, application of miR-1 failed to affect luciferase
reporter activity.
The uptake and activities of transfected miRNAs was confirmed by using
mil?-] and miR-133 standards in which the complementary sequences of miR-1 and
miR-133 were cloned downstream of luciferase gene in the pMIR-REPORT plasmid
(Fig. 23).
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We determined the effects of miR-133 on endogenous expression of HEKG at
the protein level by Western blot with SKBr3 membrane protein samples. SKBr3 was
used because it is a human ceil une that expresses endogenous HERG (17) but does
flot express the muscle-specific miR-1 or miR-133 (Supplementary Fig. 2). Our data
showed that transfectjon of miR-133 reduced HERG protein level down to —10% of
control value, and as a negative control the mutant miR-133 did flot cause any
appreciable changes (Fig. 2C). Co-application of AMO-133 nearly abolished the
effects of miR-133, verifying the specificity of the miR-133 action. Moreover,
transfection of miR-1 failed to affect HERG protein level. By comparison, miR-133
produced virtually no effects on HERG mRNA level (Fig. 2D), indicating that miR-
133 does flot affect HERG rnRNA stability.
The functional significance of ERG regulation by miR-133 was explored by
whole-ceIl patch-clamp studies of I in isolated ventricular myocytes in primary
culture. Iy density in the myocytes from DM hearts or in the myocytes from healthy
control heart transfected with miR-133 was severely diminished (Fig. 2E). The
depression induced by DM was partially reversed by AMO-133 and that induced by
exogenous miR-133 was abolished by AMO-133. AMO-133 slightly enhanced 1io in
control ceils, presumably by eliminating the repressive effects of basal endogenous
miR-133. As a negative control, miR-1 failed to affect
3.4.3 Potential Role of Serum Responsive Factor (SRF) in miR-133
Overexpression
It has been shown that expression of miR]/miR-133 is dependent upon
binding of SRF to their promoter regions (13,14), an important transcriptional factor
in cardiac cells (21-24). SRF protein level was found significantly increased in
diabetic hearts relative to healthy hearts, and so was SRF transcript level (Fig. 3A).
Incubation of the DM myocytes in primary culture with distamycin A, wbich has
been shown to selectively inhibit binding of SRF to its cis-element (25), largely
reversed the increases in miR-1/miR-]33 expression (Fig. 3B). This effect was further
confirmed by silencing of SRF using the siRNA directed against SRF (SRF-siRNA)
(Fig. 3C). Moreover, in ceils isolated from DM rabbits, SRF-siRNA, but not theC negative control siRNA, increased I density (Fig. 3D). The siRNA and distamycin
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A both slightly increased I density in healthy control ceils, presurnably by inhibiting
basal SRF. The efficiency of the $RF-siRNA in silencing SRF expression at mRNA
level was verified (Fig. 3E). Unfortunately, the primary culture did flot allow for
sufficient quantity of protein samples for Western blot analysis of SRF protein levels
or HERG protein levels.
3.5 Discussion
MiRNA-mediated gene regulation is now considered a fundamental layer of
genetic programs that operates at the post-transcriptional level. However, in spite of
our ability to identify miRNAs, regulatory targets have flot been established or even
confldenfly predicted for any of the vertebrate miRNAs, which has hampered
progress toward elucidating the functions of miRNAs. Our current understanding of
the flinctions of miRNAs primarily relies on their tissue-specific or developmental
stage-specific expression pafterns as well as their evolutionary conservation, and is
thus largely limited to biogenesis and oncogenesis. Target finding and fimction
discovery are two major challenges to researchers in miRNA research. The present
study revealed the ability of a miRNA to regulate ion channel expression and the
possible role in electrical remodeling in diabetic myocardium. It thus expanded our
understanding of the cellular function and pathophysiological roles of miRNAs in a
whole, reconsolidating the view that miRNAs likely have widespread functions in the
celis.
Our study provides an explanation for the observed discrepancy between
changes ofHERG/rbERG expression at protein and mRNA levels. In our recent smdy
on QT prolongation of diabetic hearts, we demonstrated that I density and ERG
protein level were remarkably diminished, being the major factor for QT prolongation
in diabetic rabbits, whilst ERG mRNA level was unaffected (9). Reduction of Ic due
to expression repression of HERG by miR-133 is expected to resuit in repolanzation
siowing thereby QT prolongation. In ouï recent study, we found that miR-133
repressed KCNQ1 (16), a channel protein responsible for the slow delayed rectifier
C K current (iKs) in cardiac cells. However, whether I has significant contribution to
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diabetic QT prolongation is stiil an open question and our previous studies suggest a
minimal role ofI (9,10). Nonetheless, our study points to an important role of miR-
133 in abnormal QT prolongation in diabetes and maybe in other pathological
conditions as well. Our data also indicate that the cardiac-specific miR-1 is flot
responsible for the down-regulation ofI in DM heart.
It is important to note here that the phenomenon of disparate changes of ERG
expression at protein and mRNA levels have also been observed in failing heart and
iscbemic myocardium. For example, several studies found that Ii current density was
significantly diminished in myocytes from failmg hearts that is also
electrophysiologically characterized by repolarization slowing and QT prolongation
similar to diabetic hearts, despite that the mRNA level of HERG was barely altered
under these conditions (24-29). Whether these disparate changes of ERG protein and
mRNA in failing hearts and ischemic myocardium are consequent to upregulation of
miR-133 expression is worthy ofdetailed studies.
Our smdy also provides evidence for the potential role of SRF in miR-133
overexpression in DM myocytes. The SRF-siRNA flot only nullifies the increase in
miR-133 but also rescues depressed 11Cr in DM. Whether $RF inhibition or
knockdown couÏd have beneficial effects on diabetic QT prolongation ments future
investigations.
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3.8 Figures and Figure Legends
Fig. 1. Upregulation of the muscle-specific microRNAs miR-1 and miR-133 and
downregulation of ERG (ether-a-go-go-related gene) in rabbit hearts of diabetes mode!
(rbERG, n=5 hearts for each group) and in human hearts (HERG, n=z6 hearts for each
group) from subjects with diabetes mellitus (DM). (A) and (B) Increases in mRNA
!eve!s of mil?-] and miR-133. (C) and (D) Downregulation of rbERG and HERG
protein levels in DM hearts. AP: pretreated with antigenic peptide; Ctl: age-matched
and sham-operated contro! rabbits or patients wiffi healffiy hearts. *p<0.05 vs. Ctl.
Fig. 2. Post-transcriptional repression of HERG by the musc!e-specific microRNA
miR-133. (A) Luciferase reporter activities showing the interaction between miR-133
and HERG gene. HEK293 ce!!s were co-transfected with the chimeric vector carrying
luciferase—HERG cDNA and miR-133 (10 nM and 100 nM), mutant miR-133 (M
miR-133, 100 nM), miR-133-specific antisense inhibitor oligonucleotides (AMO-133,
100 nM) or miR-1 (100 nM). Ctl: control ce!ls transfected with the chimenc vector
only. AMO-133 was co-transfected with miR-133 (100 nM). *p<005 vs. Ctl;
+p<0.05 vs. miR-133 (100 nM); n=5 for each group. (B) Luciferase reporter activities
Ç. verifying the interactions of miR-1 and miR-133 with their respective exact binding
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sequences (standards) in HEK293 ceils. AMO-1: miR-1-speciflc antisense inhi1itor;
miR-1 standard or miR-133 standard: the chimeric vectors carrying luciferase gene
and the exact miR-1 or miR-133 target sequence. AMO-1 (100 nM) was co
transfected with miR-1 (100 nM). *p<0.05 vs. Ctl; n=4 for each group. (C) Western
blot analysis of HERG protein levels with membrane protein samples isolated from
$KBr3 celis. Celis were co-transfected with the chimenc vector and miR-133 (10 or
100 nM), M-miR-133, AMO-133 or mi]?-] (100 nM). “AP+” represents pretreatment
of the antibody with its antigenic peptide. AMO-133 (100 nM) was co-transfected
with miR-133 (100 nM). *p<0.05 vs. Ctl; +p<0.05 vs. miR-133 (100 nM); n=5 for
each group. (D) Failure of miR-133 (10 and 100 nM) to affect mRNA level ofHERG
in SKBr3 ceils. The concentration of M-miR-133, AMO-133 and miR-] used for
these experiments was 100 nM. AMO-133 was co-transfected with miR-133 (100
nM). n=5 for each group. (E) Whole-cell patch-clarnp recordings of rapid delayed
rectifier K current (I, encoded by rbERG) in lefi ventricular myocytes isolated
from diabetic (DM) and healthy rabbits (Ctl). Current recording was made 24 h afier
transfection. I in display was elicited by a 2-s depolarizing voltage step to a test
potential of +10 mV from a holding potential of-60 mV (see Supplemental Figure 3
for the full range of voltages tested). AMO-133: Ctl or DM ceils treated with AMO
133 (100 nM) alone; +AMQ-133: Cii celis co-transfected with miR-133 (100 nM) and
AMO-133; miR-133 and miR-1: Ctl cells treated with miR-133 (100 nM) and miR-1
(100 nM) alone, respectively. *p<0.05 vs. Ctl or DM; +p<0.05 vs. miR-133 (100 nM)
alone; n=8 celis for each group.
Fig. 3. Role of sernm response factor (SRF) in enhancing expressions of miR-1/miR-
133 in the heart of diabetic rabbits. (A) Overexpression of SRF in hearts (lefi
ventricular wall) of diabetes mellitus (DM), detennined by Western blot analysis.
+AP: antigenic peptide treatment of the anti-SRF antibody. *p<0.05 vs. Ctl (normal
heart); n=8 hearts for each group. (B) Reversal of increased miR-1/miR-]33 levels by
SRF inhibitor distamycin A (DA) in lefi ventricular myocytes isolated from DM
rabbits. The myocytes were incubated with DA (100 nM) in normal culture medium
for 36 h before extraction of RNA samples. *p<0.05 vs. Ctl, +p<0.05 vs. DM; 11=4
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hearts for each group. (C) Reversai of increased miR-1/miR-133 levels by the siRNA
targeting SRF (SRF-siRNA) in lefi ventricular myocytes isolated from DM rabbits.
The ceils were transfected with SRF-siRNA (30 nM) or negative control siRNA (NC
siRNA, 30 nM) and 36 h after RNA samples were extracted. *p<O.05 vs. Ctl,
+p<0.05 vs. siRNA alone; n4 for each group. (D) Increase in induced by SRF
siRNA in left ventricular myocytes isolated ftom DM or healthy control (Ctl) rabbits.
The ceils were transfected with SRF-siRNA (30 nM) or negative control siRNA (NC
siRNA, 30 nM) and 36 h afier, patch-clamp recordings were performed. Ic in display
was elicited by a 2-s depolarizing voltage step to a test potential of +10 mV from a
holding potential of -60 mV (see Supplemental Figure 3 for the full range of
voltages tested). DA: distamycin A (100 nM). n=7 celis for each group except for DA
group (n5 celis). (E) Verification of the efflciency of $RF-siRNA in silencing SRF
in left ventncular myocytes isolated from DM rabbits, determined by quantitative
real-time RT-PCR methods. *p<0•05 vs. CtI, +p<0.05 vs. siRNA alone; n=3 samples
for each group.
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MICRORNA MIR-133 REPRESSES HERG K CHANNEL
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C’ Experimental
Rat Model ofMyocardial Infarction
— Male Wistar rats of 23 0-270 g were randomly
divided into control and myocardial infarction (MI) groups. Myocardial infarction
was established as previously described (1). The rats were anesthetized with diethyl
ether and were placed in the supine position with the upper limbs taped to the table.
Chest skin was cleaned with 70% ethanol and a 1—1.5 cm incision was made along
the lefi side of the sternum. The muscle layers of the chest wall were bluntly
dissected to avoid bleeding. The thorax was cut open at the point of the most
pronounced cardiac pulsation. Using forceps to widen the chest, the abdomen and the
right side of the chest were pressed to push the heart out of the thoracic cavity. The
lefi anterior descending (LAD) coronary artery was occluded and then the chest was
closed back. All surgical procedures were performed under sterile conditions. Two
days afler occlusion, the heart was removed and the tissues in ischemic zone were
dissected for RNA extraction with with Ambion’s mirVana miRNA Isolation Kit for
measurement of miR-] and miR-133 levels. Control animals underwent open-chest
procedures without coronary artery occlusion. Use of animals was in accordance with
the regulations of the ethic committee of Harbin Medical University.
Ceil Isolation and Primaiy Ceit Culture
— Neonatal rat ventricular cardiomyocytes
were isolated and cultured as described previously (2). Briefly, 1-3 days old rats were
decapitated and their hearts were aseptically removed. Their ventricles were dissected,
minced and trypsinized overnight at 4°C. The next day, celis were dissociated with
collagenase and pre-plated twice for 60 min at 37°C. The non-adherent
cardiomyocytes were removed and plated in 24-well plates in DMEM!F-12 medium
(Invifrogen) containing 10% FBS and 0.1 mM bromodeoxyuridine (Sigma). lx
cells/well were seeded in 24-well plate for further experiments. Tins procedure
yielded cultures with 95% myocytes, as assessed by microscopic observation of celi
beating.
Angiotensin II-Induced Hypertrophy and Cell Surface Area Analysis of
Cardiomyocytes — Isolated neonatal rat ventricular ceils were cultured for 24 h in
sernm-containing medium afier winch they were serum-starved for 24 h before
CI
1.33
treatment. To induce hypertrophy, celis were stimulated by angiotensin II (1 tM) for
36 h in serum-free culture medium (3,4). Celi surface area was analyzed using a
Leica inverted microscope equipped with a Polaroid digital camera at
200xmagnification. Celi area was measured using Mocha software (SPSS Inc.,
Chicago, IL). The ceils were collected for total RNA isolation using the Ambion’s
mirVana miRNA Isolation Kit for measurement of miR-1 and miR-133 levels.
Freparation ofAnimal Model of Congestive Heart Failure (CHF) — The procedures
for producing CHF dogs have been previously described in detail (5). Briefly,
mongrel dogs (25 to 33 kg) were used for our study. The right ventricle was
stimulated at 240 bpm for 3 weeks, followed by 2 weeks at 220 bpm. Dogs were
anesthetized with morphine (2 mg/kg SC) and a-chloralose (120 mg/kg W load,
29.25 mg/kg/h infusion), and a median stemotomy was perfonued. The heart was
quickly removed and the lefi ventricular endocardium was dissected. The tissue was
used for extracting RNA with Ambion’s mirVana miRNA Isolation Kit for
measurement of miR-1 and miR-133 levels.
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C FIGURE LEGENDS
Supplementary Fig. 1. Sequences of the muscle-specific miRNAs and thefr putative
target sites in human ether-a-go-go-related gene (HERG) and rabbit ether-a-go-go
related gene (rbERG). (A) The sequences ofwild-type and mutant miR-]/miR-133 and
their respective antisense inhibitors oligonucleotides (AMO-1 and AMO-133).
Boldface lefters indicate the ‘seed site’ critical for miRNA::mRNA binding and
interaction; lower-case letters indicate the base substitution mutations made to the
sequences; italics in the AMOs indicate the locked nucleotides (the ribose ring is
constrained by a methylene bridge between the 2’-O- and the 4’-C atoms, to confer a
higher thermal stability, discriminative power and a longer haif-life). AMO-1 and
AMO-133 speciflcally target miR-1 and miR-133, respectively. (B) and (C) The
complementarity between miR-133 and the putative target sites in HERG gene (B) and
rbERG gene (C). The matched base pairs are bold and connected by “I”. The
GenBank accession numbers of the genes are indicated in the brackets and the
positions of the target sites are labeled by the numbers. Note that there are multiple
putative target sites for miR-133 in HERG and rbERG.
Supplementary Fig. 2. Comparison of miR-1 and miR-133 expression levels in
various ceil unes indicated. MiR-1 and miR-133 expression levels were determined by
real-time RT-PCR using the mirVanaTM qRT-PCR miRNA Detection Kit (Ambion)
in conjunction with SYBR Green I. H9c2, rat ventricular celi line (n=6 batches of
ceils); SKBr3, human breast cancer celi line (n=6 batches cf celis); HEK293, human
embryonic kidney cell une (n=7 batches of celis). MiR-1 and miR-133 levels are
expressed as relative levels by nomializing to the values obtained from H9c2 ceils.
*p<005 vs. H9c2.
Supplementary Fig. 3. Whole-cell patch-clamp recordings of the rapid delayed
rectifier K current encoded by rbERG) in lefi ventricular myocytes isolated
from diabetic (DM) and healthy control (Ctl) rabbits. Current recording was made 24
h afier transfection. I was elicited by the voltage protocols shown in the inset at an
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interpulse interval of 10 s. (A) The data on current-voltage (I-V) relationships were
obtained from 8 celis for each group. AMO-133 (Ctl): healthy control ceils treated
with AMO-133 (100 nM); AMO-133 (DM): DM celis treated with AMO-133 (100
nM); +AMQ-133 (Ctl): Ctl celis co-transfected with miR-133 (100 nM) and AMO
133 (100 nM); miR-133 (Ctl) and miR-1 (Ctl): Ctl ceils treated with miR-133 (100 nM)
and miR-1 (100 nM) alone, respectively. The differences of Ii density (pAJpF)
between DM or miR-133 and other groups were statistically significant at voltages
from -20 mV to +40 mV. (B) Jncrease in Ic induced by SRF-siRNA in lefi
ventricular myocytes isolated from DM or Ctl rabbits. The celis were transfected with
SRF-siRNA (30 nM) or negative control siRNA (NC siRNA, 30 nM) and 36 h after,
patch-clamp recordings were performed. DA: distamycin A (100 nM). n7 ceils for
each group except for DA group (n=5 ceils).
Supplementary Figure 1
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A
miR-1
5-UGGA3JAAAGAAGUAUGUAA-3
5-caaggcacAAAGAAGUAUGUAA-3
Mutant miR-1
miR-133
5-UtJGGUCCCCUUCAACCAGCUGU-3
5-ccaacaaaCUUCAACCAGCUGU-3
Mutant miR-133
AMO-1
5- TTACATACTTCTTTCR-3
AMO-133
5’-ACAGcrGGTTGAAGGGGAœA-3
B
miR-133
3’-UJCGACCAACtJUCCCCUGGUU-5
III I I I II I
379-CACCAA-1’CACCGGGGCCCC-40O
3-UGUcGACCAACUtJCCCCUGGUU-5’
I I II I
113 3-CACœATCCACCGCTGGAccT-1154
3-UGUcGACCAACUUœCCUGGUU-5
I II II I II
171 O-GCTœACAACCTGœCGACCAG-1 731
3’-UGGACCAACUUCCCCUGGUU-5’
I 1111 I
231 6—TGA1’CCTGCGGGGGGACGTC—2337
3-GUcGACCAACuu-CCCCUGGUU-5
II II II liii
23 99-TGGCAAGTCCAACGGGGACGTG-2 420
3-UGUCGACCAACUUCCCCUGGUU-5
I I II liii
3522-CCTGGCCACGGAAGGGGAGG-3543
Rabbit ERG (GenBank: U87513)
C
miR-133
3-UGUCGACCAACUUCCCCUGGUU-5
III liii
24 66-?CATGCACCGCCAGGGGCACA-2487
3-UGUCGACCACUUCCCCUGGUU-5
11111 II 1111111
248 7—ACTGGTGCATGCTGGGGACCTG-25 08
3-UGUCG1CCAACUUCCCCUGGUU-5
I I 111111
287 7—CACGG1GCAGCCAGGGGGGTG-2 898
3’-UGUCGACCAAC-UUCCCCUGGUU-S
I I II 111111
3 173—TTTCAGCrCTGGGGGGACAGT-3 194
3-UGUCGACCAACUUCCCCUGGUU-5’
II 111111 I
374 9—CCTGACCGTGGAAGGGGAGAGG-3770
3-UGUCGACCAACUUCCCCtJGGUU-5
I II II I
378 9—CTCCCCCAGCCCTTGGGACCAT-3 810
Human ERG (GenBank: HSU04270)
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PART III. OVERALL DISCUSSION AND
CONCLUSIONS
1. Major findings
HERGJ and KCNQ] genes encode two major repolarizing K channel (IKr and
I, respectively) a-subumts that critically determine the repolarization rate and
repolarization reserve in cardiac celis thereby the likelihood of arrhythmias.
Expressions of these genes are regionally heterogeneous and change dynamically
depending on differentiation status and pathological states of the heart. Therefore,
elucidating the expression controls of HERGJ and KCNQ1 genes will greatly
advance our understanding of the molecular mechanisms underlying the electrical
remodeling during the developmental stages and pathological processes. In this thesis,
we have conducted studies on the transcriptional and post-transcriptional controls of
HERGJ and KCNQJ expressions. A number ofnovel findings are highuighted below.
First, our study identified the core promoter regions of HERG]a/HERGJb
and KCNQ]a/KCNQJb genes, which control their transcriptions. Second, our study
revealed the transcription factor Spi as a common transactivator for the promoters of
HERGJ, KCNQJ and KCNEJ genes; Spi plays an essential role in driving HERGJ,
KCNQ1 and KCNE] transcription and shows an interventricular difference of its
expression in the heart. Thïrd, our study unraveled a novel aspect of cellular function
of miRNAs: post-transcriptional repression of ion channel genes; miR-133 post
transcriptionally repressed HERG 1 and KCNQ 1, whereas KCNE 1 was validated to
be the target for repression by miR-1. Moreover, evidence was provided indicating
that miR-1/miR-133 exist heterogeneously in the different regions of the heart. And
finally, our study demonstrated that the interplay between Spi and miR-1/miR-]33
determines the expression levels of HERGJ and KCNQJ genes and the unique
regional expression profiles of Spi and miR-1/miR-133 may be one of the
mechanisms for the well-recognized regional differences ofI and IlCs.
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2. Summary and Conclusion
2.1 Identification of the core promoter regions ofHERGJ and KCNQ1 isoforms
The long QT syndrome genes HERG1 and KCNQ1, encoding K channels
critical to cardiac repolarization, are both comprised of two isoforms: HERGYa and
HERG1b, and KCNQ1a and KCNQ1b, respectively. A number of K channels have
been investigated on their genomic structures for the transcriptional regulation, with
their promoter regions identified and characterized. However, as afready mentioned
in the Introduction section, the majority of these studies have been conducted with
rat and mouse genes, and the acquired information may not be applicable to human
counterparts due to the interspecies differences especially at the 5 ‘-untranslated
region (5’-UTR) ofthe genes. Research on promoters ofhuman K channel genes has
been sparse despite that two recent studies independently reported the transcriptional
control of human KCNEJ gene encoding a family of single-transmembrane-domain
K channel -subunit that modulate the properties ofseveral K channel a-subunits’.
The promoter for regulation of gene transcription is charactenzed as the
region upstream of its transcription start site (TSS). A T$S for specific gene
transcription is normally determined by identification of its complete 5’-UTR. We
identified two distinguished T$$s for HERGJb and for KCNQ1a genes and one TS$
for HERG la and for KCNQ1b genes (Chapter 1, Fig. 1). It has been believed that the
four isoforms HERG1a/HERG1b and KCNQ1a/KCNQ1b represent altematively
spliced variants of HERG1 and KCNQ1 genes, respectively8. However, our resuits
suggest that this view needs to be modified; the four isoforms most likely represent
independent transcripts for they each have their owii unique transcription start site
and promoter region (Chapter 1, Fig. 1,2 and 3).
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C 2.2 Spi as the essential transactivators for HERGJ , KCNQJ and KCNEJ genes
Based on our smdy, the promoter regions of HERGJ, KCNQ] and KCNEJ
genes ail share a connnon feature, being GC rich in their proximal promoter regions.
Computational analysis of these proximal promoter regions reveals multiple Sp 1
consensus binding sites and the absence of TATA binding site (Chapter 1, Fig. 1;
Chapter 2, fig. 1). Spi is a widely distributed member of a multigene family of zinc
finger transcription factors that bind DNA in mammalian ceils primarily via
interaction with GC-boxes9’2. The binding of Spi to GC-boxes is shown to
significantly enhance the transcription levels of the genes whose promoters contain
no TATA site’3’5. Consistent with previous reports, our study showed Spi to act as
transactivator for HERGJ, KCNQ] and KCNEJ genes. Several unes of evidence were
obtained in support of our conclusion. First, there are multiple Sp 1 binding sites
within the core promoter regions, which are responsible for Spi activation of
HERGJ, KCNQJ and KCNE] genes transcriptional activities, characteristic of
‘house-keeping’ genes (Chapter 1, Fig. 1; Chapter 2, Fig. 1). Second, the inhibition of
Spl-DNA interaction by mithramycin significantly down-regulated both promoter
activities of HERGJa/HERGJb(not shown in this thesis from unpublished data),
KCNQ]a and KCNE1(Chapter 2, Fig. 3) as well as the endogenous transcriptions of
HERG](not shown in this thesis from unpublished data), KCNQ] and
KCNEJ(Chapter 2, Fig. 3). In contrast, overexpression of Spi boosted up their
promoter activities (Chapter 2, Fig. 3). Third, in a Spi-nuli environment (SL-2 celi)
the core promoter constructs failed to show any activities whereas when co
transfected with Spi, SL-2 cells allows promoter activation (Chapter 2, Fig. 3).
Taken together, we can make a conclusion that Spi serve as an essential
transactivator for HERG 1, KCNQ I and KCNE I genes. Moreover, the ion channels
gene promoters that have been identified to date (including the promoters in this
study), regardless of animal species, share the same general structural features
conimon to the housekeeping-type promoters. That is, the promoter lack consensus
TATA boxes and are GC-rich with multiple Spi consensus elements.
C
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C 2.3 HERGI, KCNQ1 and KCNE1 are targets for post-transcrïptional repression
by the musc]e-specific microRNAs miR-1 and miR-133
Having generated a tremendous amount of excitement about miRNAs in many
areas of biology, research over the past five years has put miRNAs at centre stage.
Indeed, miRNA-mediated gene regulation is now considered a fundamental layer of
genetic programs that operates at the post-transcriptional level. Based on
computational prediction, HERG is shown to be the target of miR-133, whereas,
neither KCNQ1 nor KCNEY were considered as candidate targets for miR-1/miR-]33,
despite that they both have substantial complementarity to the miRNAs, likely due to
unfavorable ftee energy status. By detailed analysis (basing on the complimentarity)
ofthe 3’UTR ofHERGJ and KCNQ], we identified 6 putative miR-133 binding sites
for HERGJ (Chapter 3, Supplemental Fig. 1) and four of that for KCNQ] (Chapter2,
Fig. 4A). Similarly, the 3’UTR ofKCNEJ was found containing three putative mi]?-]
binding sites (Chapter2, Fig. 5A). These multiple sites may cooperate with one
another to confer significant effects ofthe miRNAs.
In order to verify HERG1, KCNQ1 and KCNE1 are indeed the cognate
targets of miR-1/miR-133 for post-transcriptional repression, we took the following
two approaches. First, we used a cell-based luciferase reporter gene system to test the
effect of miR-1/miR-]33 on 3 ‘UTR of each gene by overexpressing or silencing these
miRNAs, which has been reported to be an effective way to study the function of
miRNAs’6’8. Second, we determined the effects of miR-1/miR-]33 on endogenous
expression of HERG1, KCNQ1 and KCNE1 at both protein and mRNA levels in
culture ceils. Our experimental data convincingly demonstrated that the expression
levels of HERG1, KCNQ1 and KCNE1 are importantly regulated by miR-133 and
miR-1, respectively. Consistent with the principle of action of miRNAs, miR-133 and
miR-1 decreased HERG1, KCNQ1 and KCNE1 protein levels without significantly
affecting their mRNA levels (Chapter 2, Fig. 4&5; Chapter 3, Fig. 2). Moreover, our
study is, to date, the first study to elucidate that the expression of ion channel genes
could be regulated flot only on their 5’UTR but also on the 3’UTR of the mRNA.
r
144
C 2.4 The spatial distribution patterns of Spi and miR-1/miR-133 and the potential
roles in regional heterogeneity of ‘Kr and I
One of the most important findings in this study is the heterogeneous
distribution of Spi and miRNAs in aduit human hearts. We assessed the expression
level of Spi and miR-]/miR-]33 at three different axes in the heart (interventricular,
transmural and apical-basal) and we found that there is an interventricular difference
of the expression of Spi (RV>LV) at both protein and mRNA levels (Chapter2, Fig
7), whereas neither miR-] nor miR-133 showed any appreciable interventricular
difference (Chapter 2, Fig. 7). Jntriguingly, both miR-] (Epi>Mid; Base>Apex) and
miR-133 (Mid>Epi; Base>Apex) appeared to have characteristic differences in their
expressions in transmural and apical-basal axes (Chapter 2, Fig. 7), whereas, in the
same axes, both protein and mRNA levels of Spi were found to be consistently
identical (Chapter 2, Fig. 7). Considering the effects of Spi and miR-]/miR-133 we
have demonstrated on regulation of HERG1, KCNQ] and KCNE] genes, it is quite
reasonable for us to question whether the heterogeneous distributions of Spi and
miR-1/miR-133 may have correlation to regional asymmetries 0f Ig.1- and ‘Ks•
For Ic1, there is not obvious transmural difference, whereas, a debatable
interventricular difference in the canine heart is reported’9. As in our studies, we tried
to reproduce the interventricular difference of ‘Kr and found that, indeed, there exist
interventricular gradients of HERG] transcripts in human heart (Chapter 1, Fig. 7).
One possible mechanism underlying this interventricular difference is through
regulating the target genes activated by dose-response transcriptional regulators
binding. In this scenario, differences in the levels of transcription factors result in the
activation or repression of diverse target genes, allowing finer control of the spatial
and temporal events of organogenesis. A recent study revealed that a transcription
factor (repressor) frx5 encoded by the Iroquois homeobox gene can repress
expression of the gene encoding Kv4.2 and is expressed with an opposite transmural
gradient to Kv4.2 is in mice20. Besides frx5, another two transcription factor genes,
frx3 and Etvi, were also found to be expressed in transmural gradients across the
ventricular walls of rat and canine hearts21. Whether these two factors play roÏes in
regional differences of K channels remained unknown, we have made a
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C comprehensive survey of HERGJ, KCNQJ and KCNE] genes’ 5’-flanking regions
using the Matlnspector program and did flot find any consensus sites as candidates
for frx3, frx5 or Etvl binding. Instead, our data point to the critical role of
transactivator Spi in HER G] transcription. First, Spi is an essential driving factor for
HERG1 transcriptions. Moreover, Spi expression demonstrates the same pattem of
interventricular gradient ofHERG] expression, at both mRNA and protein levels, and
this is in agreement with the finding that there is not interventricular difference of
miR-133. It is thus possible to conclude that the interventicular dispersion of Ici. may
be determined by Spi.
For ‘Ks, there is a well-recognized spatial heterogeneity in its distribution in
the heart, similar to the study of Ijc1, we first qualitatively reproduced the resuits
reported in previous published studies: (1) KCNQ1 and KCNE1 distribute with
significant interventricular gradients (RV>LV) at both mRNA and protein levels 22,
(2) the protein levels of both KCNQ1 and KCNE1 are higher in apical than in basal
area23, despite that their mRNA levels are flot significantly different, and (3) KCNQ1
protein level is greater in Epi than in Mid24, whereas that of KCNE1 is the opposite,
and there is not transmural difference in mRNA levels of KCNQi and KCNE125.
Clearly, in addition to the regional difference of KCNQ1 and KCNEi expressions,
there is also a consistent discrepancy between the protein and mRNA expressions of
these genes (Chapter 2, Fig. 6). Jntriguingly, the distribution patterns of Spi and miR
]/miR-]33 seem to provide a reasonable explanation for the observations and this can
be sorted out as following. First, the interventricular difference of Spi, which drives
KCNQi and KCNE1 expressions, corresponds exactly to the interventricular
differences of KCNQi and KCNE1, at both mRNA and protein levels. By
comparison, miR-1 and miR-133 do not show any chamber-dependent difference.
These suggest that the higher abundance of Spi in RV likely contributes to the higher
abundance of KCNQ1 and KCNE1 in the same chamber. Second, there is no
difference of Spi expression either across the LV wall or along the apical-basal axis,
coincident with the uniformity of distributions of KCNQi and KCNEi transcripts in
these two axes. Most strikingly, the miR-133 level was found much greater in Base
than in Apex and in Mid than in Epi. Considering the fact that miR-133 represses
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KCNQ 1 proteins leaving its transcripts unaltered, it is flot difficuit to understand why
KCNQ 1 protein levels have the opposite pattems of transmural and apical-basal
gradients to those of miR-133 but KCNQ1 mRNA does flot have transmural and
apical-basal gradients. The same logic can be applied to miR-1 and KCNE1; the
charactenstic regional distributions of miR-1, Base>Apex and Epi>Mid, can be one
of the causal factors for the converse transmural and apical-basal gradients of KCNE 1
protem levels (Chapter 2, Fig.7). It seems reasonable to corne to a conclusion that the
combination and interplay of the characteristic spatial distributions of Spi and miR
lImiR-133 account, at least partially, for the regional heterogeneity of I1-encoding
genes and the disparity between protein and rnRNA expressions ofthese genes.
3. Potential implications
In bnef, the present studies have several important pathophysiological
implications.
It is well known that the normal heterogeneities of I and Iic are crucial for
determining the normal cardiac repolanzation dispersion and abnormal repolarization
dispersion is a prerequisite for arrhythmias to occur and to sustain (such as torsade de
pointes). The normal heterogeneity of cardiac repolarization can be changed under
pathological conditions, which renders the heart a loss of the intnnsic anfiarrhythmic
mechanism and a vulnerability to arrhythmogenesis. for example, enlarged
interventricular differences have been shown to cause acquired LQTS 26;27 Our
finding that Spi and miR-133/miR-] as a potential mechanistic link for the special
heterogeneities between ion channel expressions and cardiac repolarization suggests a
new approach for antianhythmic therapy via interfering expressions of Spi and miR
133/miR-]. In the other word, Spi and miR-133/miR-] might prove novel
antiarrhythmic targets.
Second, the resuits from present studies also have some important
implications in channelopathy under various disease conditions. In our study, miR-
133 was found to be responsible for the disparate alterations of HERG protein and
rnRNA, which had been observed along with the IKJHERG channelopathy in diabetic
hearts. Moreover, it is important to note here that the phenomenon of disparate
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Ç changes ofHERG expression at protein and mRNA levels have also been observed in
failing heart and ischemic myocardium. For example, several studies found that I
current density was significantly diminished in myocytes from failing hearts that is
also electrophysiologically characterized by repolarization slowing and QT
prolongation similar to diabetic hearts, despite that the mRNA level of HERG was
barely altered under these conditions28. Whether these disparate changes of ERG
protein and mRNA in failing hearts and ischemic myocardium are consequent to
upregulation of miR-133 expression is worthy of detailed studies. Our recent paper
further demonstrated that miR-1 is an arrhythmogenic or proarrhythmic factor that is
detrimental to the ischemic heart29. Taken together, it is possible to speculate that
miR-1/miR-133 may have important pathophysiological function in the heart and may
play an essential role in disease-induced ion channel dysfunction.
Third, as afready described in the Introduction, expression of HERG and
KCNQ1 in cardiac cells changes in its abundance during the early developmental
stages with HERG and KCNQJ highly expressed in the fetal heart and dissipate in the
adult stage.30’3’ Similarly, in neural crest neurons, HERG1 currents are transiently
expressed at very early stages of their neuronal development, disappearing at later
stages to be substituted by inward rectifier-like currents32. Coincidently, Spi
expression also undergoes similar developmental alterations. Ubiquitously expressed,
this nuclear protein has been implicated in the activation or suppression of a large
number of genes and is shown to be involved in cellular process such as cell cycle
regulation, chromatin remodeling, prevention of CpG island methylation, and
apoptosis. Together this fact with the findings in the present studies, it is suggested
that Spi might be an important factor in developmental control of ion channel genes.
4. Possible limitations of the present study
It should be noted that there are some limitations in the present study. First,
the exact roles of HERGJb and KCNQJb in cardiac repolanzation and their
functional relationships with HERGJa and KCNQ1b, respectively, were not
investigated in this study. Second, we did not investigate the regional difference of
MirP-i in the present study and its possible role in determining the functional
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C dispersion of IIc. And finally, our data did flot provide enough information to
conclusively establish the pathophysiological roles of Spi and miR-1 and miR-133,
and further studies using in vivo genetic engineering of Spi arrd miR-1/rniR-133 are
absolutely needed to fully establish to unravel this issue.
5. Future Directions
Given the potential important roles of Spi and miR-]/miR-133 in determining
the regional heterogeneities of I and I, the exact pathophysiological function of
Spi and miR-1/miR-133 will need to be clarified. To achieve this goal, we could
probably use an in vivo engineered Spi- or miR-J/miR-133- knockout mice, but the
problem here will be how to examine the functional properties of HERG1 and
KCNQ1, since it lias been sliown that I and I are undetectable in the small aduit
rodent. Another aspect which will be worth of further investigation is wlietlier Spi,
per se, is also affected by miR-1/miR-133 or even some other miRNAs, although,
according to our data, tlie distribution profile of Spi in the heart were converse to
those of miR-1 and miR-133 and it is unlikely that the regional difference of Spi is
determined by either miR-1 or miR-133.
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